

US Patent & Trademark Office

Patent Public Search | Text View

United States Patent	12385063
Kind Code	B2
Date of Patent	August 12, 2025
Inventor(s)	Gonzalez Aseguinolaza; Gloria et al.

Codon-optimized ABCB11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (PFIC2)

Abstract

A gene therapy vector is used in the treatment of progressive familial intrahepatic cholestasis type 2. More specifically, an adeno-associated virus vector includes codon-optimized sequence encoding for the BSEP for the treatment of PFIC2.

Inventors:	Gonzalez Aseguinolaza; Gloria (Barañain, ES), Smerdou; Cristian (Pamplona, ES), Palomo Díaz; Laura (Basauri, ES)
Applicant:	VIVET THERAPEUTICS (Paris, FR)
Family ID:	65496678
Assignee:	VIVET THERAPEUTICS (Paris, FR)
Appl. No.:	17/291449
Filed (or PCT Filed):	November 06, 2019
PCT No.:	PCT/EP2019/080341
PCT Pub. No.:	WO2020/094693
PCT Pub. Date:	May 14, 2020

Prior Publication Data

Document Identifier	Publication Date
US 20220002751 A1	Jan. 06, 2022

Foreign Application Priority Data

EP	18306458	Nov. 07, 2018
----	----------	---------------

Publication Classification

Int. Cl.: C07H21/02 (20060101); A61K48/00 (20060101); C07K14/435 (20060101); C12N15/86 (20060101)

U.S. Cl.:

CPC C12N15/86 (20130101); A61K48/0058 (20130101); C07K14/435 (20130101); C12N2750/14123 (20130101); C12N2750/14143 (20130101); C12N2750/14152 (20130101)

Field of Classification Search

CPC: A61K (48/0058)

References Cited

U.S. PATENT DOCUMENTS

Patent No.	Issued Date	Patentee Name	U.S. Cl.	CPC
2018/0126003	12/2017	Hoerr	N/A	N/A
2020/0069817	12/2019	Liu	N/A	A61K 31/713

FOREIGN PATENT DOCUMENTS

Patent No.	Application Date	Country	CPC
107812003	12/2017	CN	N/A
2013/151666	12/2012	WO	N/A
2014/200816	12/2013	WO	N/A
2016/041588	12/2015	WO	N/A
2017/191274	12/2016	WO	N/A

OTHER PUBLICATIONS

Hayashi et al. (Hepatology, vol. 41, No. 4, 2005, pp. 916-924). cited by examiner

Dijk et al. (Clinic Rev Allerg Immunol, 2015, 48, 243-253). cited by examiner

Chin et al. (Bioinformatics, 30, 15, 2014, 2210-2212). cited by examiner

MacDonald et al. (Molecular and Cellular Endocrinology, 190, 2002, 1-8). cited by examiner

Nov. 29, 2019 International Search Report issued in International Patent Application No.

PCT/EP2019/080341. cited by applicant

Hisamitsu Hayashi et al. "Two Common PFIC2 Mutations Are Associated With the Impaired Membrane Trafficking of BSEP/ABCB11", Hepatology, vol. 41, No. 4, Mar. 24, 2005, pp. 916-924. cited by applicant

Johannes Noé et al. "Functional Expression of the Canalicular Bile Salt Export Pump of Human Liver", Gastroenterology, vol. 123, No. 5, Nov. 1, 2002, pp. 1659-1666. cited by applicant

Lin Wang et al. "The role of bile salt export pump mutations in progressive familial intrahepatic cholestasis type II," Journal of Clinical Investigation, vol. 110, No. 7, Oct. 1, 2002, pp. 965-972. cited by applicant

Lisa M. Kattenhorn et al. "Adeno-Associated Virus Gene Therapy for Liver Disease", Human Gene Therapy, vol. 27, 10. 12, Dec. 1, 2016, pp. 947-961. cited by applicant

Ping Lam et al. "Levels of plasma membrane expression in progressive and benign mutations of the bile salt export bump (Bsep/Abcb11) correlate with severity of cholestatic diseases", American

Journal of Physiology Cell Physiology, vol. 293, No. 5, 2007, pp. C1709-C1716. cited by applicant
Julien Baruteau et al. "Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects", Journal of Inherited Metabolic Disease, vol. 40, No. 4, May 31, 2017, pp. 497-517. cited by applicant
Wendy L van der Woerd et al. "Current and future therapies for inherited cholestatic liver diseases". World Journal of Gastroenterology, vol. 23, No. 5, Jan. 7, 2017, pp. 763-775. cited by applicant
Jesus Prieto et al. "Gene therapy of liver diseases", Expert Opinion on Biological Therapy, vol. 4, No. 7, Jul. 1, 2004, pp. 1073-1091. cited by applicant
Saskia W. C. Van Mil et al. "Benign Recurrent Intrahepatic Cholestasis Type 2 is Caused by Mutations in ABCB11", Gastroenterology, vol. 127, No. 2, Aug. 1, 2004, pp. 379-384. cited by applicant
Nov. 29, 2019 Written Opinion issued in International Patent Application No. PCT/EP2019/080341. cited by applicant
Raab, David et al. "The Geneoptimizer Algorithm: Using a Sliding Window Approach to Cope With the Vast Sequence Space in Multiparameter DNA Sequence Optimization". Syst Synth Biol (2010) 4:215-225. cited by applicant
Mauro, Vincent P. "Codon Optimization in the Production of Recombinant Biotherapeutics: Potential Risks and Considerations". BioDrugs (2018) 32:69-81. cited by applicant
Feb. 14, 2023 Office Action issued in European Patent Application No. 19795591.7. cited by applicant

Primary Examiner: Hudson; Amy Rose

Attorney, Agent or Firm: Oliff PLC

Background/Summary

FIELD OF THE INVENTION

(1) The present disclosure relates to gene therapy vector for use in the treatment of progressive familial intrahepatic cholestasis type 2. More specifically, the present invention relates to an adeno-associated virus vector comprising codon-optimized sequence encoding for the BSEP for the treatment of PFIC2.

BACKGROUND ART

(2) Progressive familial intrahepatic cholestasis 2 (PFIC2) is a genetic disease associated with mutations in the ABCB11 gene which expresses bile salt export pump (BSEP), a 1,321 amino-acids protein with molecular mass of ~160 kDa (Kubitz, R. et al. 2012; Clin Res Hepatol Gas 36(6): 536-553). BSEP is expressed predominantly in the canalicular membranes of hepatocytes and is involved in the transport of bile salts from these cells to the bile (Jacquemin, E. 2012. Clin Res Hepatol Gas 36 Suppl 1: S26-S35). The signs and symptoms of PFIC2 are typically related to liver disease only. People with PFIC2 often develop liver failure within the first few years of life. Additionally, affected individuals are at increased risk of developing hepatocellular carcinoma. PFIC2 causes bile acid to accumulate in the liver leading to decreased bile acids excretion and therefore accumulation in hepatocytes (intrahepatic cholestasis). Cellular bile accumulation leads to hepatocyte death, bile release in blood, severe pruritus, evolution to portal hypertension, liver failure and cirrhosis, and ultimately death in untreated patients. PFIC2 is a rare disease with an estimated incidence of 1 per 100,000 births although the exact prevalence is not known (Gonzales, E. et al. 2014. Eur J Hum Genet 22(4)). The disease affects both genders equally and has been reported from around the world.

(3) There is currently no cure for PFIC2, and therefore the unmet medical need is very high. Although ursodeoxycholic acid (UDCA) therapy may ameliorate symptoms in some patients, outside of liver transplant there is currently no curing treatment for PFIC2 (van der Woerd, W. L et al. World J Gastroentero. 2017; 23(5):763-775). Surgical intervention in the form of biliary diversion improves patient outcomes. However, post-surgical complications such as infections and issues with stoma bags impact patients' quality of life, while the risk of cirrhosis and liver cancer still remains. Liver transplants are an effective treatment, but carry with them the risks involved with such a complicated procedure as well as a chance of re-emergence of the condition. Despite current available treatments, the quality of life and the life expectancy of patients with PFIC2 are still limited.

(4) Gene therapy correcting the defective gene responsible for disease development is a promising treatment for a number of diseases. However, the technique remains still under study. RNA therapy to treat a liver condition such as progressive familial intrahepatic cholestasis 2 (PFIC2) using various potential therapeutic genes including ABCB11 was only suggested in WO2017/100551 or WO2017/001570. Thus, there is still a need to develop gene therapy methods which allow stable and long-term transgene expression.

(5) Herein, it is described a new type of therapy for PFIC2 based on the delivery to the liver of a codon-optimized version of the ABCB11 gene, by using an adeno-associated virus (AAV) as a vector.

SUMMARY OF THE INVENTION

(6) Surprisingly, the inventors found that contrary to the wild type human BSEP-coding gene (BSEP), the codon optimized sequence of BSEP encoding gene when administered in vivo showed an efficient expression specifically in the canalicular membranes of hepatocytes. In *Abcb11.sup.-/-* knock-out mice which reproduce most of PFIC2 symptoms observed in patients, administration of AAV bearing a codon-optimized cDNA versions encoding BSEP achieve a therapeutic effect such as significant decrease of transaminases and restoration of the secretion of bile salts to bile.

(7) A first aspect of the present disclosure thus relates to a nucleic acid construct comprising a transgene encoding BSEP, said transgene is the sequence SEQ ID NO: 1 or a sequence having at least 80% of identity with SEQ ID NO: 1.

(8) In specific embodiments, said nucleic acid construct further comprises a promoter which initiates transgene expression upon introduction into a host cell, preferably a liver specific promoter, more preferably an alpha-1-antitrypsin promoter or a bile salt-inducible promoter.

(9) In specific embodiments, said nucleic acid construct further comprises a 5'ITR (inverted terminal repeat) and a 3'ITR sequences, preferably a 5'ITR and a 3'ITR sequences of adeno-associated virus (AAV), notably a 5'ITR and a 3'ITR sequences from the AAV2 serotype.

(10) In more specific embodiments, said nucleic acid construct comprises or consists of the nucleic acid sequence SEQ ID NO: 3 or a nucleic acid sequence having at least 80% of identity with SEQ ID NO: 3.

(11) In another aspect, said nucleic acid construct is comprised in an expression vector, preferably a viral vector, more preferably an AAV vector.

(12) Another aspect of the present disclosure relates to a viral particle comprising a nucleic acid construct or an expression vector of the invention and preferably comprising capsid proteins of adeno-associated virus such as capsid proteins selected from the group consisting of: AAV3 type 3a, AAV3 type 3B, NP40, NP59, NP84, LK03, AAV3-ST, Anc80 and AAV8 serotype.

(13) Another aspect of the present disclosure relates to a host cell comprising the nucleic acid construct or the expression vector of the invention, or a host cell transduced with a viral particle of the invention.

(14) Another aspect of the present disclosure relates to a pharmaceutical composition comprising the nucleic acid construct, expression vector, host cell, or viral particle of the invention, in combination with one or more pharmaceutical acceptable excipient.

(15) The invention also relates to a product of the invention for use as a medicament, such as the prevention and/or the treatment of progressive familial intrahepatic cholestasis type 2 in a subject in need thereof. In a specific embodiment, the subject is a neonate, an infant, a child or an adult, preferably a neonate, an infant or a child, more preferably a neonate or an infant. Also disclosed herein is a process for producing viral particles as described above, comprising the steps of: a) culturing a host cell as described above in a culture medium, and b) harvesting the viral particles from the cell culture supernatant and/or inside the cells.

(16) The present disclosure also relates to a kit comprising the nucleic acid construct, the expression vector, the host cell, the viral particle, or the pharmaceutical composition as described above, in one or more containers, optionally further comprising instructions or packaging materials.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

- (1) FIG. 1. Diagram of AAVAnc80-wt-hBSEP and AAVAnc80-co-hBSEP vectors used in experiments. A1AT Pr.: A1AT promoter; ITR: inverted terminal repeats; pA: synthetic polyadenylation sequence
- (2) FIG. 2. Immunofluorescence of cells transfected with AAV plasmids expressing hBSEP. Huh-7 and HepG2 cells were transfected with pAAV-co-hBSEP and pAAV-wt-hBSEP vectors and analyzed by immunofluorescence with a specific anti-hBSEP antibody after 72 h. Nuclei were stained with DAPI. Magnification: 400×.
- (3) FIG. 3. AAVAnc80 liver transduction in Abcb11.sup.-/- and Abcb11.sup.+/+ mice. Female mice having the indicated genotypes received 2×10¹³ vg/kg of AAVAnc80-co-hBSEP, AAVAnc80-wt-hBSEP or an equivalent volume of saline. Mice were sacrificed one month later and AAV viral DNA (A) or hBSEP mRNA levels (B) were quantified in liver extracts by qPCR or RT-qPCR, respectively. ΔCt corresponds to Ct for house-keeping gene GAPDH—Ct for A1AT promoter sequence (A) or Ct for house-keeping gene GAPDH—Ct for human ABCB11 codon optimized or non-codon optimized gene (B).
- (4) FIG. 4. hBSEP expression in vivo. Four-week-old female Abcb11.sup.-/- mice received 2×10¹³ vg/mL of AAVAnc80-co-hBSEP or AAVAnc80-wt-hBSEP and expression was analyzed one month later by immunohistochemistry. Female Abcb11.sup.+/+ mice were used as positive control for hBSEP staining (left panel). Female Abcb11.sup.-/- mice receiving AAVAnc80-co-hBSEP are in the middle panel. The arrow indicates one of the very few hBSEP positive cells detected in mice receiving AAVAnc80-wt-hBSEP (right panel). Representative pictures from two mice in each group are shown.
- (5) FIG. 5. Serum markers in Abcb11.sup.-/- and Abcb11.sup.+/+ mice. ALP, ALT, AST, and bilirubin serum biomarkers were analyzed in the serum of Abcb11.sup.-/- (KO) and Abcb11.sup.+/+ (WT) mice (n>5 in all groups) at the indicated age (months) using a COBAS analyzer (Roche). The statistical analysis was performed using a ManWhitney test (signs above KO bars show comparison with WT mice of the same age and gender; horizontal bars show comparisons between male and female KO of the same age). *, p<0.05; **, p<0.01; ***, p<0.001; ns, not significant; U/L, units/L
- (6) FIG. 6. ALP, transaminase, and bilirubin levels in Abcb11.sup.-/- mice after AAVAnc80-co-hBSEP treatment. Four-week old Abcb11.sup.-/- mice were treated with 6×10¹³ vg/kg of AAVAnc80-co-hBSEP (+BSEP) or left untreated (nt) and the levels of ALP, ALT, AST, and bilirubin were determined in serum at the indicated mice ages (n>7 in all groups). Empty bars correspond to basal levels in treated mice. The statistical analysis was performed using a ManWhitney test. *, p<0.05; **, p<0.01; ns, non-significant.
- (7) FIG. 7. Biliary bile salt levels in Abcb11.sup.-/- mice one month after AAVAnc80-co-hBSEP

treatment. Four-week old Abcb11.sup.-/- mice (n=3 or 4) were treated with 6×10¹³ vg/kg or left untreated and one month later mice were sacrificed and the level of bile salts in bile were determined with a COBAS analyzer (Roche) and compared to Abcb11.sup.+/+ mice of the same age. The statistical analysis was performed using a ManWhitney test. *, p<0.05.

(8) FIG. 8. Serum markers in Abcb11.sup.-/- mice treated with AAV vectors expressing BSEP. Four-week old Abcb11.sup.-/- mice (KO) were treated with 6×10¹³ vg/kg of AAVAnc80-co-hBSEP (AAVAnc80-BSEP), AAV8-co-hBSEP (AAV8-BSEP) or left untreated (No treat.). Levels of AST (A) and bilirubin (B) were determined in serum at the indicated ages (months, n>4 in all groups) using a COBAS analyzer (Roche). Non-treated Abcb11.sup.+/+ mice (WT) were used as controls. Empty bars correspond to basal levels in treated mice. Statistical analysis was performed comparing treated and non-treated KO mice of the same age using a ManWhitney test. *, p<0.05; **, p<0.01; ***, p<0.001. U/L, units/L.

(9) FIG. 9. Liver weight in Abcb11.sup.-/- mice treated with AAV vectors expressing BSEP. Four-week old Abcb11.sup.-/- mice (KO) were treated with AAVAnc80-co-hBSEP and AAV8-co-hBSEP as described in FIG. 8. Liver weight (A) and the ratio of liver/body weight (B) were determined at the indicated ages (months). Non-treated Abcb11.sup.+/+ mice (WT) were used as controls. Statistical analysis was performed comparing treated and non-treated KO mice of the same age using a ManWhitney test. *, p<0.05; **, p<0.01; ***, p<0.001, ****, p<0.0001.

(10) FIG. 10. Secretion of bile salts in Abcb11.sup.-/- mice treated with AAV vectors expressing BSEP. Four-week old Abcb11.sup.-/- mice (KO) were treated with AAVAnc80-co-hBSEP and AAV8-co-hBSEP as described in FIG. 8. Mice were sacrificed at two months of age and bile salt levels were determined in bile (A) and small intestine (B) with a COBAS analyzer (Roche). Numbers above the bars indicate the percentage of bile salts related to levels present in Abcb11.sup.+/+ mice (WT). The statistical analysis was performed using a ManWhitney test. *, p<0.05, **p<0.01.

DETAILED DESCRIPTION

(11) The invention relates to a transgene comprising a codon-optimized sequence encoding bile salt export pump (BSEP) (NCBI reference sequence: NP_003733.2). The membrane-associated protein encoded by ABCB11 gene, also named BSEP gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. This gene encodes a liver resident transporter protein which plays an essential role in the enterohepatic circulation of the bile salts. Mutations in this gene cause a form of progressive familial intrahepatic cholestasis which are a group of inherited disorders with severe cholestatic liver disease from early infancy.

(12) As used herein, the term “transgene” refers to exogenous DNA or cDNA encoding a gene product. The gene product may be an RNA, peptide or protein. In addition to the coding region for the gene product, the transgene may include or be associated with one or more elements to facilitate or enhance expression, such as a promoter, enhancer(s), response element(s), reporter element(s), insulator element(s), polyadenylation signal(s) and/or other functional elements. Embodiments of the invention may utilize any known suitable promoter, enhancer(s), response element(s), reporter element(s), insulator element(s), polyadenylation signal(s) and/or other functional elements. Suitable elements and sequences will be well known to those skilled in the art.

(13) Nucleic Acid Construct

(14) More particularly, the invention relates to a nucleic acid construct comprising a transgene encoding BSEP, said transgene is the sequence SEQ ID NO: 1 or 2 or a sequence having at least 80% identity with SEQ ID NO: 1 or 2.

(15) The terms “nucleic acid sequence” and “nucleotide sequence” may be used interchangeably to refer to any molecule composed of or comprising monomeric nucleotides. A nucleic acid may be an oligonucleotide or a polynucleotide. A nucleotide sequence may be a DNA or RNA. A nucleotide sequence may be chemically modified or artificial. Nucleotide sequences include peptide nucleic acids (PNA), morpholinos and locked nucleic acids (LNA), as well as glycol nucleic acids (GNA)

and threose nucleic acid (TNA). Each of these sequences is distinguished from naturally-occurring DNA or RNA by changes to the backbone of the molecule. Also, phosphorothioate nucleotides may be used. Other deoxynucleotide analogs include methylphosphonates, phosphoramidates, phosphorodithioates, N3'P5'-phosphoramidates and oligoribonucleotide phosphorothioates and their 2'-O-allyl analogs and 2'-O-methylribonucleotide methylphosphonates which may be used in a nucleotide of the invention.

(16) The term “nucleic acid construct” as used herein refers to a man-made nucleic acid molecule resulting from the use of recombinant DNA technology. A nucleic acid construct is a nucleic acid molecule, either single- or double-stranded, which has been modified to contain segments of nucleic acids sequences, which are combined and juxtaposed in a manner, which would not otherwise exist in nature. A nucleic acid construct usually is a “vector”, i.e. a nucleic acid molecule which is used to deliver exogenously created DNA into a host cell.

(17) As used herein, the term “sequence identity” or “identity” refers to the number of matches (identical nucleic acid residues) in positions from an alignment of two polynucleotide sequences. The sequence identity is determined by comparing the sequences when aligned so as to maximize overlap and identity while minimizing sequence gaps. In particular, sequence identity may be determined using any of a number of mathematical global or local alignment algorithms, depending on the length of the two sequences. Sequences of similar lengths are preferably aligned using a global alignment algorithms (e.g. Needleman and Wunsch algorithm; Needleman and Wunsch, 1970, J Mol Biol.; 48(3):443-53) which aligns the sequences optimally over the entire length, while sequences of substantially different lengths are preferably aligned using a local alignment algorithm (e.g. Smith and Waterman algorithm (Smith and Waterman, 1981, J Theor Biol; 91(2):379-80) or Altschul algorithm (Altschul S F et al., 1997, Nucleic Acids Res; 25(17):3389-402.; Altschul S F et al., 2005, Bioinformatics; 21(8):1451-6)). Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software available on internet web sites such as <http://blast.ncbi.nlm.nih.gov/> or <http://www.ebi.ac.uk/Tools/emboss/>). Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, % nucleic acid sequence identity values refers to values generated using the pair wise sequence alignment program EMBOSS Needle that creates an optimal global alignment of two sequences using the Needleman-Wunsch algorithm, wherein all search parameters are set to default values, i.e. Scoring matrix=BLOSUM62, Gap open=10, Gap extend=0.5, End gap penalty=false, End gap open=10 and End gap extend=0.5.

(18) As used herein, said nucleic acid construct comprises a transgene encoding BSEP according to the invention and one or more control sequence required for expression of said coding sequence. Generally, the nucleic acid construct comprises a coding sequence and regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence that are required for expression of the selected gene product. Thus, a nucleic acid construct typically comprises a promoter sequence, a coding sequence and a 3' untranslated region that usually contains a polyadenylation site and/or transcription terminator. The nucleic acid construct may also comprise additional regulatory elements such as, for example, enhancer sequences, a polylinker sequence facilitating the insertion of a DNA fragment within a vector and/or splicing signal sequences.

(19) In one embodiment, the nucleic acid construct comprises a promoter. Said promoter initiates transgene expression upon introduction into a host cell. As used herein, the term “promoter” refers to a regulatory element that directs the transcription of a nucleic acid to which it is operably linked. A promoter can regulate both rate and efficiency of transcription of an operably linked nucleic acid. A promoter may also be operably linked to other regulatory elements which enhance (“enhancers”) or repress (“repressors”) promoter-dependent transcription of a nucleic acid. These regulatory

elements include, without limitation, transcription factor binding sites, repressor and activator protein binding sites, and any other sequences of nucleotides known to one of skill in the art to act directly or indirectly to regulate the amount of transcription from the promoter, including e.g. attenuators, enhancers, and silencers. The promoter is located near the transcription start site of the gene or coding sequence to which it is operably linked, on the same strand and upstream of the DNA sequence (towards the 5' region of the sense strand). A promoter can be about 100-1000 base pairs long. Positions in a promoter are designated relative to the transcriptional start site for a particular gene (i.e., positions upstream are negative numbers counting back from -1, for example -100 is a position 100 base pairs upstream).

(20) As used herein, the term “operably linked” refers to a linkage of polynucleotide (or polypeptide) elements in a functional relationship. A nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter or transcription regulatory sequence is operably linked to a coding sequence if it affects the transcription of the coding sequence. Operably linked means that the DNA sequences being linked are typically contiguous; where it is necessary to join two protein encoding regions, they are contiguous and in reading frame.

(21) In a particular embodiment, the nucleic acid construct of the invention further comprises a liver-specific promoter operably-linked to the transgene of the invention. In the context of this invention, a “liver-specific promoter” is a promoter which is more active in the liver than in any other tissue of the body. Typically, the activity of a liver specific promoter will be considerably greater in the liver than in other tissues. For example, such a promoter may be at least 2, at least 3, at least 4, at least 5 or at least 10 times more active (for example as determined by its ability to drive the expression in a given tissue in comparison to its ability to drive the expression in other cells or tissues). Accordingly, a liver specific promoter allows an active expression in the liver of the gene linked to it and prevents its expression in other cells or tissues.

(22) In one embodiment, the liver-specific promoter comprises a nucleotide sequence of the α 1-antitrypsin gene promoter (AAT or A1AT) (SEQ ID NO: 5), a bile salt-inducible promoter (SEQ ID NO: 6 or 7) or a chimeric promoter sequence EalbPa1AT that comprises a α 1-antitrypsin gene promoter sequence (AAT or Pa1AT) combined with an albumin gene enhancer element (Ealb). All these promoter sequences have properties of liver specific promoters.

(23) Each of these nucleic acid construct embodiments may also include a polyadenylation signal sequence; together or not with other optional nucleotide elements. As used herein, the term “polyadenylation signal” or “poly(A) signal” refers to a specific recognition sequence within 3' untranslated region (3' UTR) of the gene, which is transcribed into precursor mRNA molecule and guides the termination of the gene transcription. Poly(A) signal acts as a signal for the endonucleolytic cleavage of the newly formed precursor mRNA at its 3'-end, and for the addition to this 3'-end of a RNA stretch consisting only of adenine bases (polyadenylation process; poly(A) tail). Poly(A) tail is important for the nuclear export, translation, and stability of mRNA. In the context of the invention, the polyadenylation signal is a recognition sequence that can direct polyadenylation of mammalian genes and/or viral genes, in mammalian cells.

(24) Poly(A) signals typically consist of a) a consensus sequence AAUAAA, which has been shown to be required for both 3'-end cleavage and polyadenylation of premessenger RNA (pre-mRNA) as well as to promote downstream transcriptional termination, and b) additional elements upstream and downstream of AAUAAA that control the efficiency of utilization of AAUAAA as a poly(A) signal. There is considerable variability in these motifs in mammalian genes.

(25) In one embodiment, the polyadenylation signal sequence of the nucleic acid construct of the invention is a polyadenylation signal sequence of a mammalian gene or a viral gene. Suitable polyadenylation signals include, among others, a SV40 early polyadenylation signal, a SV40 late polyadenylation signal, a HSV thymidine kinase polyadenylation signal, a protamine gene polyadenylation signal, an adenovirus 5 E1b polyadenylation signal, a growth hormone

polydenylation signal, a PBGD polyadenylation signal, in silico designed polyadenylation signal (synthetic) and the like.

(26) In a particular embodiment, the polyadenylation signal sequence of the nucleic acid construct is a synthetic poly(A) signal sequence based on the rabbit beta-globin gene, more particularly a synthetic poly(A) having sequence SEQ ID NO: 8.

(27) Expression Vector

(28) The nucleic acid construct of the invention may be comprised in an expression vector. As used herein, the term “expression vector” refers to a nucleic acid molecule used as a vehicle to transfer genetic material, and in particular to deliver a nucleic acid into a host cell, either in vitro or in vivo. Expression vector also refers to a nucleic acid molecule capable of effecting expression of a gene (transgene) in host cells or host organisms compatible with such sequences. Expression vectors typically include at least suitable transcription regulatory sequences and optionally 3'-transcription termination signals. Additional factors necessary or helpful in effecting expression may also be present, such as expression enhancer elements able to respond to a precise inductive signal (endogenous or chimeric transcription factors) or specific for certain cells, organs or tissues. Vectors include, but are not limited to, plasmids, phasmids, cosmids, transposable elements, viruses, and artificial chromosomes (e.g., YACs). Preferably, the vector of the invention is a vector suitable for use in gene or cell therapy, and in particular is suitable to target liver cells.

(29) In some embodiments, the expression vector is a viral vector, such as vectors derived from Moloney murine leukemia virus vectors (MoMLV), MSCV, SFFV, MPSV or SNV, lentiviral vectors (e.g. derived from human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) or equine infectious anemia virus (EIAV)), adenoviral (Ad) vectors, adeno-associated viral (AAV) vectors, simian virus 40 (SV-40) vectors, bovine papilloma virus vectors, Epstein-Barr virus, herpes virus vectors, vaccinia virus vectors, Harvey murine sarcoma virus vectors, murine mammary tumor virus vectors, Rous sarcoma virus vectors.

(30) As is known in the art, depending on the specific viral vector considered for use, suitable sequences should be introduced in the vector of the invention for obtaining a functional viral vector, such as AAV ITRs for an AAV vector, or LTRs for lentiviral vectors. In a particular embodiment, said vector is an AAV vector.

(31) AAV has arisen considerable interest as a potential vector for human gene therapy. Among the favourable properties of the virus are its lack of association with any human disease, its ability to infect both dividing and non-dividing cells, and the wide range of cell lines derived from different tissues that can be infected. The AAV genome is composed of a linear, single-stranded DNA molecule which contains 4681 bases (Berns and Bohenzky, 1987, *Advances in Virus Research* (Academic Press, Inc.) 32:243-307). The genome includes inverted terminal repeats (ITRs) at each end, which function in cis as origins of DNA replication and as packaging signals for the virus. The ITRs are approximately 145 bp in length. The internal non-repeated portion of the genome includes two large open reading frames, known as the AAV rep and cap genes, respectively. These genes code for the viral proteins involved in replication and packaging of the virion. In particular, at least four viral proteins are synthesized from the AAV rep gene, Rep 78, Rep 68, Rep 52 and Rep 40, named according to their apparent molecular weight. The AAV cap gene encodes at least three proteins, VP1, VP2 and VP3. For a detailed description of the AAV genome, see, e.g., Muzyczka, N. 1992 *Current Topics in Microbiol. and Immunol.* 158:97-129.

(32) Thus, in one embodiment, the nucleic acid construct or expression vector comprising transgene of the invention further comprises a 5'ITR and a 3'ITR sequences, preferably a 5'ITR and a 3' ITR sequences of an adeno-associated virus.

(33) As used herein the term “inverted terminal repeat (ITR)” refers to a nucleotide sequence located at the 5'-end (5'ITR) and a nucleotide sequence located at the 3'-end (3'ITR) of a virus, that contain palindromic sequences and that can fold over to form T-shaped hairpin structures that

function as primers during initiation of DNA replication. They are also needed for viral genome integration into the host genome; for the rescue from the host genome; and for the encapsidation of viral nucleic acid into mature virions. The ITRs are required in cis for the vector genome replication and its packaging into the viral particles.

(34) AAV ITRs for use in the viral vector of the invention may have a wild-type nucleotide sequence or may be altered by the insertion, deletion or substitution. The serotype of the inverted terminal repeats (ITRs) of the AAV may be selected from any known human or nonhuman AAV serotype. In specific embodiments, the nucleic acid construct or viral expression vector may be carried out by using ITRs of any AAV serotype, including AAV1, AAV2, AAV3 (including types 3A and 3B), AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, avian AAV, bovine AAV, canine AAV, equine AAV, ovine AAV, and any other AAV serotype now known or later discovered.

(35) In one embodiment, the nucleic acid construct further comprises a 5'ITR and a 3'ITR of an AAV of a serotype AAV2.

(36) In a particular embodiment, the nucleic acid construct of the invention comprises or consists of SEQ ID NO: 3 or 4 or a sequence having at least 80% of identity with SEQ ID NO: 3 or 4.

(37) In one embodiment, the nucleic acid construct or AAV vector genome according to the invention is comprised in a recombinant baculovirus genome. As used herein, the term "recombinant baculovirus genome" refers to a nucleic acid that comprises baculoviral genetic elements for autonomous replication of a recombinant baculovirus genome in a host cell permissive for baculovirus infection and replication, typically insect cells. The term "recombinant baculovirus genome" expressly includes genomes comprising nucleic acids that are heterologous to the baculovirus. Likewise, the term "recombinant baculovirus genome" does not necessarily refer to a complete baculovirus genome as the genome may lack viral sequences that are not necessary for completion of an infection cycle. In particular, the recombinant baculovirus genomes may include the heterologous AAV genes useful for rAAV production and/or the transgene such as codon-optimized BSEP cDNA to be encapsidated in the rAAV for use in gene therapy. The baculoviral genetic elements for use in the present disclosure are preferably obtained from AcMNPV baculovirus (*Autographa californica* multinucleocapsid nucleopolyhedrovirus).

(38) In a particular embodiment, the genes encoding baculovirus cathepsin and chitinase in said first and second baculoviral genomes are disrupted or deleted. In particular, the genes v-cath (Ac127) and chiA (Ac126) of the AcMNPV baculovirus may be disrupted or deleted so that the corresponding cathepsin or chitinase are either not expressed or expressed as inactive forms (i.e. have no enzymatic cathepsin or chitinase activity). In a particular embodiment, said recombinant baculovirus genomes are further disrupted or deleted for at least p24 gene (Ac129), preferably for the three baculoviral genes p10 (Ac137), p24 and p26 (Ac136). In a particular embodiment, said recombinant baculovirus genomes include functional p74 baculoviral gene (Ac138) (i.e. said gene has not been deleted or disrupted).

(39) On the other hand, the nucleic acid construct or expression vector of the invention can be carried out by using synthetic 5'ITR and/or 3'ITR; and also by using a 5'ITR and a 3'ITR which come from viruses of different serotypes. All other viral genes required for viral vector replication can be provided in trans within the virus-producing cells (packaging cells) as described below. Therefore, their inclusion in the viral vector is optional.

(40) In one embodiment, the nucleic acid construct or viral vector of the invention comprises a 5'ITR, a ψ packaging signal, and a 3'ITR of a virus. " ψ packaging signal" is a cis-acting nucleotide sequence of the virus genome, which in some viruses (e.g. adenoviruses, lentiviruses . . .) is essential for the process of packaging the virus genome into the viral capsid during replication.

(41) The construction of recombinant AAV viral particles is generally known in the art and has been described for instance in U.S. Pat. Nos. 5,173,414 and 5,139,941; WO 92/01070, WO 93/03769, Lebkowski et al. (1988) Molec. Cell. Biol. 8:3988-3996; Vincent et al. (1990) Vaccines

90 (Cold Spring Harbor Laboratory Press); Carter, B. J. (1992) *Current Opinion in Biotechnology* 3:533-539; Muzyczka, N. (1992) *Current Topics in Microbiol. and Immunol.* 158:97-129; and Kotin, R. M. (1994) *Human Gene Therapy* 5:793-801.

(42) Viral Particle

(43) The nucleic acid construct or the expression vector of the invention may be packaged into a virus capsid to generate a “viral particle”, also named “viral vector particle”. In a particular embodiment, the nucleic acid construct or the expression vector of the invention is packaged into an AAV-derived capsid to generate an “adeno-associated viral particle” or “AAV particle”. The present invention relates to a viral particle comprising a nucleic acid construct or an expression vector of the invention and preferably comprising capsid proteins of adeno-associated virus.

(44) The term AAV vector particle encompasses any recombinant AAV vector particle or mutant AAV vector particle, genetically engineered. A recombinant AAV particle may be prepared by encapsidating the nucleic acid construct or viral expression vector including ITR(s) derived from a particular AAV serotype on a viral particle formed by natural or mutant Cap proteins corresponding to an AAV of the same or different serotype.

(45) Proteins of the viral capsid of an adeno-associated virus include the capsid proteins VP1, VP2, and VP3. Differences among the capsid protein sequences of the various AAV serotypes result in the use of different cell surface receptors for cell entry. In combination with alternative intracellular processing pathways, this gives rise to distinct tissue tropisms for each AAV serotype.

(46) Several techniques have been developed to modify and improve the structural and functional properties of naturally occurring AAV viral particles (Bünning H et al. *J Gene Med*, 2008; 10: 717-733; Paulk et al. *Mol ther.* 2018; 26(1):289-303; Wang L et al. *Mol Ther.* 2015; 23(12):1877-87; Vercauteren et al. *Mol Ther.* 2016; 24(6):1042-1049; Zinn E et al., *Cell Rep.* 2015; 12(6):1056-68).

(47) Thus, in AAV viral particle according to the present disclosure, the nucleic acid construct or viral expression vector including ITR(s) of a given AAV serotype can be packaged, for example, into: a) a viral particle constituted of capsid proteins derived from the same or different AAV serotype [e.g. AAV2 ITRs and AAV5 capsid proteins; AAV2 ITRs and AAV8 capsid proteins; AAV2 ITRs and Anc80 capsid proteins; AAV2 ITRs and AAV9 capsid proteins]; b) a mosaic viral particle constituted of a mixture of capsid proteins from different AAV serotypes or mutants [e.g. AAV2 ITRs with AAV1 and AAV5 capsid proteins]; c) a chimeric viral particle constituted of capsid proteins that have been truncated by domain swapping between different AAV serotypes or variants [e.g. AAV2 ITRs with AAV5 capsid proteins with AAV3 domains].

(48) The skilled person will appreciate that the AAV viral particle for use according to the present disclosure may comprise capsid proteins from any AAV serotype including AAV1, AAV2, AAV3 (including types 3A and 3B), AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, avian AAV, bovine AAV, canine AAV, equine AAV, ovine AAV, synthetic AAV variants such as NP40, NP59, NP84 (Paulk et al. *Mol ther.* 2018.26(1):289-303), LK03 (Wang L et al. *Mol Ther.* 2015. 23(12):1877-87), AAV3-ST (Vercauteren et al. *Mol Ther.* 2016.24(6):1042-1049), Anc80 (Zinn E et al., *Cell Rep.* 2015; 12(6):1056-68) and any other AAV serotype now known or later discovered.

(49) In a specific embodiment, the AAV viral particle comprises capsid proteins from a serotype selected from the group consisting of an AAV1, AAV3B, an AAV5, an AAV7, an AAV8, and an AAV9 which are more suitable for delivery to the liver cells (Nathwani et al. *Blood* 2007; 109: 1414-1421; Kitajima et al. *Atherosclerosis* 2006; 186:65-73).

(50) In a particular embodiment, the AAV viral particle comprises capsid proteins from Anc80, a predicted ancestor of viral AAVs serotypes 1, 2, 8, and 9 that behaves as a highly potent gene therapy vector for targeting liver, muscle and retina (Zinn E et al., *Cell Rep.* 2015; 12(6):1056-68). In a more particular embodiment, the viral particle comprises the Anc80L65 VP3 capsid protein (Genbank accession number: KT235804).

(51) Thus, in a further aspect, the present invention relates to a viral particle comprising a nucleic

acid construct or expression vector of the invention and preferably comprising capsid proteins of adeno-associated virus such as capsid proteins from Anc80.

(52) In a particular embodiment, the viral particle comprises AAV vector genome comprised in recombinant baculovirus. Thus, a second recombinant baculovirus genome comprising AAV rep and cap is used for producing AAV viral particle. In a particular embodiment, the rep and cap proteins are expressed from distinct baculovirus late promoters, preferably in inverse orientation. In a specific embodiment, that may be combined with the previous embodiments, the second baculovirus genome include a heterologous nucleic acid encoding the rep proteins, for example, rep proteins from AAV2 under the transcriptional control of the baculovirus polyhedron (P.sub.Ph) promoter. In other embodiment, the second baculovirus genome includes a heterologous nucleic acid encoding the cap proteins under the transcriptional control of the p10 baculovirus promoter. Other modifications of the wild-type AAV sequences for proper expression in insect cells and/or to increase yield of VP and virion or to alter tropism or reduce antigenicity of the virion are also known in the art. By using helper baculoviral construct encoding the rep ORF (open reading frame) of an AAV serotype and cap ORF of a different serotype AAV, it is feasible packaging a vector flanked by ITRs of a given AAV serotype into virions assembled from structural capsid proteins of a different serotype. It is also possible by this same procedure to package mosaic, chimeric or targeted vectors.

(53) Virus-glycan interactions are critical determinants of host cell invasion. In a particular embodiment, the AAV viral particle comprises capsid proteins comprising one or more amino acids substitutions, wherein the substitutions introduce a new glycan binding site into the AAV capsid protein. In a more particular embodiment, the amino acid substitutions are in amino acid 266, amino acids 463-475 and amino acids 499-502 in AAV2 or the corresponding amino acid positions in AAV1, AAV3, AAV4, AAV5, AAV6, AAV7, AAV 8, AAV9, AAV10 or any other AAV serotype, also included Anc80 and Anc80L65.

(54) The introduced new glycan binding site can be a hexose binding site [e.g. a galactose (Gal), a mannose (Man), a glucose (Glu) or a fucose (fuc) binding site]; a sialic acid (Sia) binding site [e.g. a Sia residue such as is N-acetylneuraminic acid (NeuSAc) or N-Glycolylneuraminic acid (NeuSGc)]; or a disaccharide binding site, wherein the disaccharide is a sialic acid linked to galactose, for instance in the form of Sia(alpha2,3)Gal or Sia(alpha2,6)Gal. Detailed guidance to introduce a new binding site from an AAV serotype into a capsid protein of an AAV of another serotype is given on international patent publication WO2014144229 and in Shen et al. (J. Biol. Chem. 2013; 288(40):28814-28823). In a particular embodiment, the Gal binding site from AAV9 is introduced into the AAV2 VP3 backbone resulting in a dual glycan-binding AAV strain which is able to use both HS and Gal receptors for cell entry. Preferably, said dual glycan-binding AAV strain is AAV2G9. Shen et al. generated AAV2G9 by substituting amino acid residues directly involved and immediately flanking the Gal recognition site on the AAV9 VP3 capsid protein subunit onto corresponding residues on the AAV2 VP3 subunit coding region (AAV2 VP3 numbering Q464V, A467P, D469N, I470M, R471A, D472V, S474G, Y500F, and S501A).

(55) In another embodiment, the viral particle for use according to the present disclosure may be an adenoviral particle, such as an Ad5 viral particle. As it is the case for AAV viral particle, capsid proteins of Ad viral particles can also be engineered to modify their tropism and cellular targeting properties, alternative adenoviral serotypes can also be employed.

(56) A Process for Producing Viral Particles

(57) Production of viral particles carrying the expression viral vector as disclosed above can be performed by means of conventional methods and protocols, which are selected taking into account the structural features chosen for the actual embodiment of expression vector and viral particle of the vector to be produced.

(58) Briefly, viral particles can be produced in a host cell, more particularly in specific virus-producing cell (packaging cell), which is transfected with the nucleic acid construct or expression

vector to be packaged, in the presence of a helper vector or virus or other DNA construct(s).

(59) The term “packaging cells” as used herein, refers to a cell or cell line which may be transfected with a nucleic acid construct or expression vector of the invention and provides in trans all the missing functions which are required for the complete replication and packaging of a viral vector. Typically, the packaging cells express in a constitutive or inducible manner one or more of said missing viral functions. Said packaging cells can be adherent or suspension cells.

(60) Typically, a process of producing viral particles comprises the following steps:

(61) a) culturing a packaging cell comprising a nucleic acid construct or expression vector as described above in a culture medium; and

(62) b) harvesting the viral particles from the cell culture supernatant and/or inside the cells.

(63) Conventional methods can be used to produce AAV viral particles which consist on transient cell co-transfection with nucleic acid construct or expression vector (e.g. a plasmid) carrying the transgene of the invention; a nucleic acid construct (e.g., an AAV helper plasmid) that encodes rep and cap genes, but does not carry ITR sequences; and with a third nucleic acid construct (e.g., a plasmid) providing the adenoviral functions necessary for AAV replication.

(64) Viral genes necessary for AAV replication are referred herein as viral helper genes. Typically, said genes necessary for AAV replication are adenoviral helper genes, such as E1A, E1B, E2a, E4, or VA RNAs. Preferably, the adenoviral helper genes are of the Ad5 or Ad2 serotype.

(65) Large-scale production of AAV particles according to the disclosure can also be carried out for example by infection of insect cells with a combination of recombinant baculoviruses (Urabe et al. Hum. Gene Ther. 2002; 13: 1935-1943). SF9 cells are co-infected with two or three baculovirus vectors respectively expressing AAV rep, AAV cap and the AAV vector to be packaged. The recombinant baculovirus vectors will provide the viral helper gene functions required for virus replication and/or packaging. Smith et al 2009 (Molecular Therapy, vol. 17, no. 11, pp 1888-1896) further describes a dual baculovirus expression system for large-scale production of AAV particles in insect cells.

(66) Suitable culture media will be known to a person skilled in the art. The ingredients that compose such media may vary depending on the type of cell to be cultured. In addition to nutrient composition, osmolarity and pH are considered important parameters of culture media. The cell growth medium comprises a number of ingredients well known by the person skilled in the art, including amino acids, vitamins, organic and inorganic salts, sources of carbohydrate, lipids, trace elements (CuSO₄, FeSO₄, Fe(NO₃)₃, ZnSO₄ . . .), each ingredient being present in an amount which supports the cultivation of a cell in vitro (i.e., survival and growth of cells). Ingredients may also include different auxiliary substances, such as buffer substances (like sodium bicarbonate, Hepes, Tris . . .), oxidation stabilizers, stabilizers to counteract mechanical stress, protease inhibitors, animal growth factors, plant hydrolyzates, anti-clumping agents, anti-foaming agents. Characteristics and compositions of the cell growth media vary depending on the particular cellular requirements. Examples of commercially available cell growth media are: MEM (Minimum Essential Medium), BME (Basal Medium Eagle) DMEM (Dulbecco's modified Eagle's Medium), Iscoves DMEM (Iscove's modification of Dulbecco's Medium), GMEM, RPMI 1640, Leibovitz L-15, McCoy's, Medium 199, Ham (Ham's Media) F10 and derivatives, Ham F12, DMEM/F12, etc.

(67) Further guidance for the construction and production of viral vectors for use according to the disclosure can be found in Viral Vectors for Gene Therapy, Methods and Protocols. Series: Methods in Molecular Biology, Vol. 737. Merten and Al-Rubeai (Eds.); 2011 Humana Press (Springer); Gene Therapy. M. Giacca. 2010 Springer-Verlag; Heilbronn R. and Weger S. Viral Vectors for Gene Transfer: Current Status of Gene Therapeutics. In: Drug Delivery, Handbook of Experimental Pharmacology 197; M. Schafer-Korting (Ed.). 2010 Springer-Verlag; pp. 143-170; Adeno-Associated Virus: Methods and Protocols. R. O. Snyder and P. Moullier (Eds). 2011 Humana Press (Springer); Bünning H. et al. Recent developments in adeno-associated virus technology. J. Gene Med. 2008; 10:717-733; Adenovirus: Methods and Protocols. M. Chillón and A. Bosch (Eds.);

(68) Host Cells

(69) In another aspect, the invention relates to a host cell comprising a nucleic acid construct or an expression vector of the invention. More particularly, host cell according to the invention is a specific virus-producing cell, also named packaging cell which is transfected with the nucleic acid construct or expression vector according to the invention, in the presence of a helper vector or virus or other DNA constructs and provides in trans all the missing functions which are required for the complete replication and packaging of a viral particle. Said packaging cells can be adherent or suspension cells

(70) For example, said packaging cells may be eukaryotic cells such as mammalian cells, including simian, human, dog and rodent cells. Examples of human cells are PER.C6 cells (WO01/38362), MRC-5 (ATCC CCL-171), WI-38 (ATCC CCL-75), HEK-293 cells (ATCC CRL-1573), HeLa cells (ATCC CCL2) and fetal rhesus lung cells (ATCC CL-160). Examples of non-human primate cells are Vero cells (ATCC CCL81), COS-1 cells (ATCC CRL-1650) or COS-7 cells (ATCC CRL-1651). Examples of dog cells are MDCK cells (ATCC CCL-34). Examples of rodent cells are hamster cells, such as BHK21-F, HKCC cells, or CHO cells.

(71) As an alternative to mammalian sources, the packaging cells for producing the viral particles may be derived from avian sources such as chicken, duck, goose, quail or pheasant. Examples of avian cell lines include avian embryonic stem cells (WO01/85938 and WO03/076601), immortalized duck retina cells (WO2005/042728), and avian embryonic stem cell derived cells, including chicken cells (WO2006/108846) or duck cells, such as EB66 cell line (WO2008/129058 & WO2008/142124).

(72) In another embodiment, the cells can be any cells permissive for baculovirus infection and replication packaging cells. In a particular embodiment, said cells are insect cells, such as SF9 cells (ATCC CRL-1711), Sf21 cells (IPLB-Sf21), MG1 cells (BTI-TN-MG1) or High Five™ cells (BTI-TN-5B1-4).

(73) Accordingly, in a particular embodiment, the host cell comprises: a nucleic acid construct or expression vector comprising a transgene encoding BSEP according to the invention (e.g., the AAV vector according to the invention), a nucleic acid construct, for example a plasmid, encoding AAV rep and/or cap genes which does not carry the ITR sequences; and/or a nucleic acid construct, for example a plasmid or virus, comprising viral helper genes.

(74) In another aspect, the invention relates to a host cell transduced with a viral particle of the invention and the term “host cell” as used herein refers to any cell line that is susceptible to infection by a virus of interest, and amenable to culture in vitro.

(75) The host cell of the invention may be used for ex vivo gene therapy purposes. In such embodiments, the cells are transduced with the viral particle of the invention and subsequently transplanted to the patient or subject. Transplanted cells can have an autologous, allogenic or heterologous origin. For clinical use, cell isolation will generally be carried out under Good Manufacturing Practices (GMP) conditions. Before transplantation, cell quality and absence of microbial or other contaminants is typically checked and liver preconditioning, such as with radiation and/or an immunosuppressive treatment, may be carried out. Furthermore, the host cells may be transplanted together with growth factors to stimulate cell proliferation and/or differentiation, such as Hepatocyte Growth Factor (HGF).

(76) In a particular embodiment, the host cell is used for ex vivo gene therapy into the liver. Preferably, said cells are eukaryotic cells such as mammalian cells, these include, but are not limited to, humans, non-human primates such as apes; chimpanzees; monkeys, and orangutans, domesticated animals, including dogs and cats, as well as livestock such as horses, cattle, pigs, sheep, and goats, or other mammalian species including, without limitation, mice, rats, guinea pigs, rabbits, hamsters, and the like. A person skilled in the art will choose the more appropriate cells according to the patient or subject to be transplanted.

(77) Said host cell may be a cell with self-renewal and pluripotency properties, such as stem cells or induced pluripotent stem cells. Stem cells are preferably mesenchymal stem cells. Mesenchymal stem cells (MSCs) are capable of differentiating into at least one of an osteoblast, a chondrocyte, an adipocyte, or a myocyte and may be isolated from any type of tissue. Generally MSCs will be isolated from bone marrow, adipose tissue, umbilical cord, or peripheral blood. Methods for obtaining thereof are well known to a person skilled in the art. Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. Yamanaka et al. induced iPS cells by transferring the Oct3/4, Sox2, Klf4 and c-Myc genes into mouse and human fibroblasts, and forcing the cells to express the genes (WO 2007/069666). Thomson et al. subsequently produced human iPS cells using Nanog and Lin28 in place of Klf4 and c-Myc (WO 2008/118820).

(78) Said host cells may also be hepatocytes. Hepatocyte transplantation procedures, including cell isolation and subsequent transplantation into a human or mice recipient is described for instance in Filippi and Dhawan, *Ann NY Acad Sci.* 2014, 1315 50-55; Yoshida et al., *Gastroenterology* 1996, 111: 1654-1660; Irani et al. *Molecular Therapy* 2001, 3:3, 302-309; and Vogel et al. *J Inherit Metab Dis* 2014, 37:165-176. A method for ex vivo transduction of a viral particle into hepatocytes is described for instance in Merle et al., *Scandinavian Journal of Gastroenterology* 2006, 41:8, 974-982.

(79) Pharmaceutical Compositions

(80) Another aspect of the present disclosure relates to a pharmaceutical composition comprising a nucleic acid construct, an expression vector, a viral particle or a host cell of the invention in combination with one or more pharmaceutical acceptable excipient, diluent or carrier.

(81) As used herein, the term “pharmaceutically acceptable” means approved by a regulatory agency or recognized pharmacopeia such as European Pharmacopeia, for use in animals and/or humans. The term “excipient” refers to a diluent, adjuvant, carrier, or vehicle with which the therapeutic agent is administered.

(82) Any suitable pharmaceutically acceptable carrier, diluent or excipient can be used in the preparation of a pharmaceutical composition (See e.g., Remington: The Science and Practice of Pharmacy, Alfonso R. Gennaro (Editor) Mack Publishing Company, April 1997). Pharmaceutical compositions are typically sterile and stable under the conditions of manufacture and storage. Pharmaceutical compositions may be formulated as solutions (e.g. saline, dextrose solution, or buffered solution, or other pharmaceutically acceptable sterile fluids), microemulsions, liposomes, or other ordered structure suitable to accommodate a high product concentration (e.g. microparticles or nanoparticles). The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.

(83) Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin. The product of the invention may be administered in a controlled release formulation, for example in a composition which includes a slow release polymer or other carriers that protect the product against rapid release, including implants and microencapsulated delivery systems. Biodegradable and biocompatible polymers may for example be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid and polylactic/polyglycolic copolymers (PLG). Preferably, said pharmaceutical composition is formulated as a solution, more preferably as an optionally buffered saline solution. Supplementary active compounds can also be incorporated into the pharmaceutical compositions of the invention. Guidance on co-administration of additional

therapeutics can for example be found in the Compendium of Pharmaceutical and Specialties (CPS) of the Canadian Pharmacists Association.

(84) In one embodiment, the pharmaceutical composition is a parenteral pharmaceutical composition, including a composition suitable for intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular administration. These pharmaceutical compositions are exemplary only and do not limit the pharmaceutical compositions suitable for other parenteral and non-parenteral administration routes. The pharmaceutical compositions described herein can be packaged in single unit dosage or in multidosage forms.

(85) Therapeutic Uses

(86) In a further aspect, the invention relates to a nucleic acid construct, expression vector, viral particle, host cell or pharmaceutical composition of the invention for use as a medicament in a subject in need thereof.

(87) The term “subject” or “patient” as used herein, refers to mammals. Mammalian species that can benefit from the disclosed methods of treatment include, but are not limited to, humans, non-human primates such as apes, chimpanzees, monkeys, and orangutans, domesticated animals, including dogs and cats, as well as livestock such as horses, cattle, pigs, sheep, and goats, or other mammalian species including, without limitation, mice, rats, guinea pigs, rabbits, hamsters, and the like. In particular embodiment, said subject is neonate, an infant or, a child, more particularly a neonate or an infant. As used herein “neonate” refers to a baby who is less than 28 days and “infants” as used herein refers to a child who is between 29 days and 2 years.

(88) In an additional aspect, the invention relates to a nucleic acid construct, expression vector, viral particle, host cell or pharmaceutical composition of the invention for use in the treatment of a liver disease, in particular progressive familial intrahepatic cholestasis type 2 (PFIC2) in a subject in need thereof.

(89) As used herein, the term “treatment”, “treat” or “treating” refers to any act intended to ameliorate the health status of patients such as therapy, prevention, prophylaxis and retardation of the disease. In certain embodiments, such term refers to the amelioration or eradication of a disease or symptoms associated with a disease. According to the present invention, examples of symptoms associated with PFIC2 are hepatocyte death, decreased bile flow and accumulation of bile salts inside the hepatocyte and in blood, severe pruritus, permanent jaundice, evolution to portal hypertension, liver failure and cirrhosis. In other embodiments, this term refers to minimizing the spread or worsening of the disease resulting from the administration of one or more therapeutic agents to a subject with such a disease.

(90) In a particular embodiment, liver disease is selected from the group consisting of: PFIC2, BRIC-2 (benign recurrent intrahepatic cholestasis type 2) or ICP (Intrahepatic cholestasis of pregnancy), drug induced cholestasis and transient neonatal cholestasis.

(91) In a more particular embodiment, said liver disease is PFIC2.

(92) In a related aspect, the invention pertains to the use of a nucleic acid construct, expression vector, viral particle, host cell or pharmaceutical composition of the invention in the preparation of a medicament for use in the treatment of a liver disease, preferably for use in the treatment of PFIC2.

(93) In a further aspect, the invention relates to a method of treating and/or preventing a liver disease, preferably PFIC2, in a subject in need thereof that comprises administering to the subject a therapeutically effective amount of a nucleic acid construct, expression vector, viral particle, host cell or pharmaceutical composition of the invention.

(94) In the context of the invention, an “effective amount” means a therapeutically effective amount.

(95) As used herein a “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary to achieve the desired therapeutic result, such as amelioration or restoration of secretion of bile salts to bile. The therapeutically effective amount of the product of

the invention, or pharmaceutical composition that comprises it may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the product or pharmaceutical composition to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also typically one in which any toxic or detrimental effect of the product or pharmaceutical composition is outweighed by the therapeutically beneficial effects.

(96) The treatment with a product of the invention may alleviate, ameliorate, or reduce the severity of one or more symptoms of PFIC2. For example, treatment may increase and/or restore secretion of bile salts to bile; decrease the amount of bile salts in liver and blood, decrease pruritus, decrease liver damage reducing transaminase levels in serum, and as a consequence may alleviate, ameliorate, or reduce the severity of the disease

(97) The product of the invention will be typically included in a pharmaceutical composition or medicament, optionally in combination with a pharmaceutical carrier, diluent and/or adjuvant. Such composition or medicinal product comprises the product of the invention in an effective amount, sufficient to provide a desired therapeutic effect, and a pharmaceutically acceptable carrier or excipient.

(98) In one embodiment the nucleic acid construct, expression vector, viral particle, host cell or pharmaceutical composition for its therapeutic use is administered to the subject or patient by a parenteral route, in particular by intravenous, intraarterial, subcutaneous, intraperitoneal, or intramuscular route.

(99) In one embodiment, the nucleic acid construct, expression vector, viral particle, host cell or pharmaceutical composition for its therapeutic use is administered by interstitial route, i.e. by injection to or into the interstices of a tissue. The tissue target may be specific, for example the liver tissue, or it may be a combination of several tissues, for example the muscle and liver tissues. Exemplary tissue targets may include liver, skeletal muscle, heart muscle, adipose deposits, kidney, lung, vascular endothelium, epithelial and/or hematopoietic cells. In a preferred embodiment, it is administered by intrahepatic injection, i.e. injection into the interstitial space of hepatic tissue.

(100) The amount of product of the invention that is administered to the subject or patient may vary depending on the particular circumstances of the individual subject or patient including, age, sex, and weight of the individual; the nature and stage of the disease, the aggressiveness of the disease; the route of administration; and/or concomitant medication that has been prescribed to the subject or patient. Dosage regimens may be adjusted to provide the optimum therapeutic response.

(101) For any particular subject, specific dosage regimens may be adjusted over time according to the individual needs and the professional judgment of the person administering or supervising the administration of the compositions. Dosage ranges set forth herein are exemplary only and do not limit the dosage ranges that may be selected by medical practitioners.

(102) In one embodiment, an AAV viral particle according to the invention can be administered to the subject or patient for the treatment of PFIC2 disease in an amount or dose comprised within a range of 5×10^{11} to 1×10^{15} vg/kg (vg: viral genomes; kg: subject's or patient's body weight). In a more particular embodiment, the AAV viral particle is administered in an amount comprised within a range of 1×10^{13} to 1×10^{14} vg/kg. In a more particular embodiment, the AAV viral particle is administered at a dosage of at least 2×10^{13} vg/kg, preferably 3.5×10^{13} vg/kg, more preferably 5×10^{13} vg/kg, and more preferably 6×10^{13} vg/kg.

(103) Kit

(104) In another aspect, the invention further relates to a kit comprising a nucleic acid construct, expression vector, host cell, viral particle or pharmaceutical composition of the invention in one or more containers. The kit may include instructions or packaging materials that describe how to administer the nucleic acid construct, expression vector, viral particle, host cell or pharmaceutical compositions contained within the kit to a patient. Containers of the kit can be of any suitable material, e.g., glass, plastic, metal, etc., and of any suitable size, shape, or configuration. In certain

embodiments, the kits may include one or more ampoules or syringes that contain the products of the invention in a suitable liquid or solution form.

(105) The following examples are provided by way of illustration, and they are not intended to be limiting of the present invention. Furthermore, the present invention covers all possible combinations of particular and preferred embodiments described herein.

EXAMPLES

(106) Molecular Engineering of Plasmid Containing the AAV Vectors Genome Bearing the Human ABCB11 cDNA Downstream of the Alpha-1 Antitrypsin (A1AT) Promoter.

(107) The human ATP binding cassette subfamily B member 11 (ABCB11) gene, also called bile salt export pump (hBSEP) gene, cDNA sequence (3,963 bp) was used to generate two plasmids allowing further AAV particle production bearing either the wild-type hBSEP cDNA or a codon optimized version of it. For both plasmids, the cDNA sequence was cloned downstream of the A1AT promoter, and this expression cassette was further inserted into an AAV2 DNA backbone using a pAAV2 plasmid (Agilent Technologies, Santa Clara, CA).

(108) For generating the co-hBSEP bearing plasmid, a synthetic DNA cassette was generated (GeneScript, Piscataway, NJ) containing the A1AT promoter upstream a codon-optimized hBSEP cDNA sequence based on the human ABCB11 protein (NCBI Reference Sequence: NP_003733.2). This cassette was then inserted between the two internal terminal repeats (ITR) of an AAV2 plasmid backbone (pAAV2), generating the pAAV-co-hBSEP. The resulting AAV-co-hBSEP vector genome has a size of 4,734 b, which is within the packaging limits of AAV particles. The pAAV-co-hBSEP was controlled by sequencing and restriction enzyme analysis. This plasmid allows for the generation of the AAV-co-hBSEP vector of any serotype or capsid variant.

(109) The wild-type hBSEP (wt-hBSEP) cDNA bearing plasmid was generated by substituting in pAAV-co-hBSEP the Sal I-Nde I fragment (4,004 bp) containing the co-hBSEP cDNA by a sequence of identical length containing the wt-hBSEP cDNA (NCBI Reference Sequence: NM_003742.4). This last sequence was also synthesized (GeneScript) and cloned into the pAAV2 plasmid. This cloning presented difficulties and could only be achieved by growing bacterial colonies at 30° C. instead of 37° C., since this last temperature resulted in undesired plasmid rearrangements. The resulting pAAV-wt-hBSEP plasmid containing AAV-wt-hBSEP vector sequence (4,734 pb) was verified by sequencing and restriction analysis. This plasmid allows for the generation of the AAV-wt-hBSEP vector of any serotype or capsid variant.

(110) The diagram showing the two AAVAnc80 vectors (of the same length) is presented FIG. 1.

(111) Analysis of BSEP Expression in Human Hepatic Cells

(112) Huh-7 and HepG2 cells were transfected with the plasmids pAAV-co-hBSEP and pAAV-wt-hBSEP using lipofectamin 2000. Cells were fixed at 48-72 h and human BSEP was detected by immunofluorescence using a primary mouse antibody specific for BSEP (Santa Cruz sc-74500; working dilution 1:1500) (FIG. 2). A donkey anti-mouse IgG Alexa-488-conjugated secondary antibody (Invitrogen ref. A21202; working dilution 1:1,000) was used for detection. As show in FIG. 2, both plasmids can express specific hBSEP in both cell lines with most cells showing membrane localization of the protein.

(113) Production of AAVAnc80 Viral Particles Containing ABCB11 cDNA Expressing hBSEP

(114) The inventors produced AAV vectors based on the in silico designed AAV ancestral sequence Anc80 (Zinn, E., et al. Cell Reports, 2015; 12:1056-1068). To produce AAVAnc80 viral particles (VPs), thirty 150-cm.sup.2-flasks containing confluent HEK293T cell monolayers were co-transfected with plasmids pδF6, pAnc80-AAP2, and the AAV plasmid containing the vector sequence to be packaged (AAV-co-hBSEP or AAV-wt-hBSEP) using polyethylenimine (PEI). After 72 h of incubation, AAV particles were purified from the supernatant and cells by ultracentrifugation using a iodixanol gradient as described (Murillo, O., et al. Journal of Hepatology, 2016; 64:419-426). Finally, the purified virus was concentrated using Amicon Ultra Centrifugal Filters-Ultracel 100K (Millipore) and titrated by qPCR using oligonucleotides specific

for the A1AT promoter (Forward primer: 5'-TTGCTCCTCCGATAACTGGG-3' (SEQ ID NO: 9); Reverse primer: 5'-CCCTGTCCTCGTCCGTATTT-3' (SEQ ID NO: 10)).

(115) Several batches were generated for each vector, which titers are indicated in Table 1.

Unexpectedly, AAVAnc80-wt-hBSEP was very difficult to produce, with only one out of six stocks generated having a sufficient titer compatible with in vivo application (above 5×10^{11} vg/mL). On the opposite, twelve batches of AAVAnc80-co-hBSEP out of 14 were produced within the expected yield and titer, only two batches showing titers below 5×10^{11} vg/mL.

(116) TABLE-US-00001 TABLE 1 Titers of AAVAnc80-hBSEP viral stocks* Stock AAVAnc80-co-hBSEP AAVAnc80-wt-hBSEP number (vg/mL) (vg/mL)

1	2.81×10^{12}	4.89×10^{12}
2	6.80×10^{11}	2.60×10^{11}
3	3.29×10^{12}	0.74×10^{10}
4	8.82×10^{12}	5.42×10^{10}
5	1.18×10^{12}	7.95×10^{10}
6	2.70×10^{11}	4.70×10^{11}
7	1.45×10^{12}	6.80×10^{11}
8	6.19×10^{12}	3.34×10^{12}
9	2.04×10^{12}	5.85×10^{12}
10	2.94×10^{12}	2.86×10^{12}
11	1.07×10^{12}	2.53×10^{12}
12	2.13×10^{12}	2.13×10^{12}
13		
14		

Mean 2.86×10^{12} 1.07×10^{12} SD 2.53×10^{12} 2.13×10^{12} *Stocks with a titer $< 5 \times 10^{11}$ vg/ml (too low to be used in vivo) are indicated in bold

Evaluation of BSEP Expression in Abcb11.sup.-/- Mice Injected with AAVAnc80 Particles

(117) In order to test the expression of hBSEP in vivo, the inventors used the C57BL/6 knock-out mouse model for Abcb11 gene (Abcb11.sup.-/- mice), which do not to express BSEP (Zhang, Y. Y., et al. Journal of Biological Chemistry, 2012, 287: 24784-24794). Four-week-old Abcb11.sup.-/- female mice were injected intravenously, using the retro-orbital route, with 2×10^{13} vg/kg of AAVAnc80-wt-hBSEP (n=2), AAVAnc80-co-hBSEP (n=3), or with an equivalent volume of saline (n=3). Wild-type mice (Abcb11.sup.+/+) were also inoculated with the same amount of vectors to compare the transduction efficacy of AAV vectors between Abcb11.sup.-/- and Abcb11.sup.+/+ mice. One month later, mice were sacrificed and liver samples were obtained. Liver homogenates were used to determine the amount of viral genomes and hBSEP mRNA in each mouse by quantitative PCR (qPCR) and reverse transcription (RT)-qPCR, respectively. In the first case, DNA was extracted using the Nucleospin tissue purification kit (Macherey Nagel) following the manufacturer's instructions, and a qPCR was performed with oligonucleotides specific for the A1AT promoter sequence (see primer sequences in previous part). Although both AAV vectors showed a similar level of AAV DNA in Abcb11.sup.+/+ mice, the AAVAnc80-wt-hBSEP vector had lower level of AAV DNA than AAVAnc80-co-hBSEP in Abcb11.sup.-/- mice (FIG. 3A). To determine the level of hBSEP mRNA expression, RNA was extracted from liver samples with the Maxwell® 16 LEV simplyRNA tissue kit (Promega), following the manufacturer's instructions. In this case, a RT reaction was first performed with random primers followed by a qPCR with primers specific for either codon optimized or wild type ABCB11 genes (for wt-hBSEP: 5'-TCATCCGAAATCCCAAGATT-3' (SEQ ID NO: 11) and 5'-CAAGCGATGAGCAACTGAA-3' (SEQ ID NO: 12); for co-hBSEP 5'-TAATTTCCAGGGCAAGATCG-3' (SEQ ID NO: 13) and 5'-AGCAGCTGGATAGAGGTGGA-3' (SEQ ID NO: 14). Although the results for both vectors cannot be directly compared due to the difference in the set of primers used to specifically amplify each of the two vectors, mRNA levels were 5 to 10 fold higher in Abcb11.sup.++ mice compared to Abcb11.sup.-/- mice for each vector (FIG. 3B). In both cases, the primers that were used did not detect murine Abcb11 mRNA, as shown by the very low signal obtained in mice that did not receive AAV vectors.

(118) Finally, hBSEP expression was analyzed in liver samples by immunohistochemistry using a BSEP specific antibody conjugated with horseradish peroxidase (Santa Cruz sc-74500). This analysis showed a strong hBSEP expression in Abcb11.sup.-/- mice that had received the AAVAnc80-co-hBSEP vector, in which a clear canaliculi staining was observed, similar to Abcb11.sup.+/+ mice used as control (FIG. 4, left and middle panels). In contrast, and unexpectedly, Abcb11.sup.-/- mice that were inoculated with AAVAnc80-wt-hBSEP showed very few cells expressing BSEP, which in addition had a very weak staining (FIG. 4, right panel),

indicating that this cDNA sequence is not efficiently suitable for hBSEP expression in vivo.

(119) Therapeutic Efficacy of AAVAnc80-Co-hBSEP in Abcb11.sup.-/- Mice

(120) For this experiment, the inventors used Abcb11.sup.-/- mice, which reproduce most of PFIC2 symptoms observed in patients, having a more severe phenotype in females compared to males. These mice show elevation of transaminases (ALT and AST), alkaline phosphatase (ALP, a cholestasis marker), bilirubin, and develop liver fibrosis (Zhang, Y. Y., et al. Journal of Biological Chemistry, 2012, 287: 24784-24794) (FIG. 5). These symptoms develop after two months of age in females but take up to six months to appear in male animals. In contrast to patients, bile salts are not elevated in Abcb11.sup.-/- mice (data not shown). In addition, both male and female Abcb11.sup.-/- mice show a dramatic decrease of biliary bile salts as early as one month of age (FIG. 7).

(121) Four week old Abcb11.sup.-/- female and male mice were injected intravenously, using the retro-orbital route, with 6×10^{13} vg/kg AAVAnc80-co-hBSEP. Non-treated mice were used as controls. Mice were bled at 1, 2, and 3 or 4 months after treatment and the following parameters were measured in serum: ALP, ALT and AST, bile salts, cholesterol, and bilirubin. No significant changes were observed in bile salts and cholesterol, as expected for this model (data not shown). Female Abcb11.sup.-/- mice that received AAVAnc80-co-hBSEP showed a significant decrease in ALT and AST at one and two months after treatment, and of bilirubin at two months post-treatment (FIG. 6). In the case of male Abcb11.sup.-/- treated mice, transaminase and bilirubin levels were similar to those of non-treated mice, but at this age these markers are within the normal range in healthy mice (mean for Abcb11.sup.+/+ mice: ALT=47.5 U/L; AST=83.25 U/L; bilirubin: 0.08 mg/dL). ALP levels diminished with age in all mice, but the reduction observed in treated females two months after treatment was higher (3 fold) compared to non-treated females (2.2 fold). It is important to notice that ALP levels in Abcb11.sup.-/- mice are only slightly elevated compared to Abcb11.sup.+/+ mice (FIG. 5). Finally, treated Abcb11.sup.-/- mice significantly increased biliary bile salt levels one month after treatment (FIG. 7), partially restoring the secretion of bile salts to bile, which is the main biomarker of PFIC2 patients, indicating a physiologic rescue of BSEP activity.

(122) Long-Term Follow-Up of Abcb11.sup.-/- Female Mice Treated with AAVAnc80-Co-hBSEP

(123) In this study, the inventors used Abcb11.sup.-/- female mice, since only mice of this gender reproduce PFIC2 symptoms observed in patients (see FIG. 5). Four-week old Abcb11.sup.-/- female mice were injected intravenously, using the retro-orbital route, with 6×10^{13} viral genomes (vg)/kg of AAVAnc80-co-hBSEP. Mice were sacrificed at one (n=6), three (n=6), and five (n=10) months after treatment. Mice were also bled at 1, 2, 3, and 5 months after treatment (mice sacrificed at one and three months after treatment were only bled until these time points). Non-treated Abcb11.sup.-/- and Abcb11.sup.+/+ mice were used as negative and positive controls, respectively. Abcb11.sup.-/- mice that received AAVAnc80-co-hBSEP showed a significant reduction of serum biomarkers, like AST and bilirubin, up to five months post-treatment when compared with non-treated Abcb11.sup.-/- mice (FIG. 8A-B). In addition, treated Abcb11.sup.-/- mice also showed a significant reduction in liver weight and liver/body ratio compared to non-treated Abcb11.sup.-/- mice at all measured times (FIG. 9A-B). These data indicated that AAVAnc80-co-hBSEP-based therapy was able to control the progression of the disease in Abcb11.sup.-/- female mice. In order to determine whether the therapeutic effect was due to the restoration of bile salt secretion from hepatocytes to bile, the inventors measured the amount of bile salts in bile and small intestine of treated Abcb11.sup.-/- mice one month after treatment. As shown in FIG. 10, treatment with AAVAnc80-co-hBSEP was able to partially restore bile salt secretion in Abcb11.sup.-/- female mice, reaching levels that represented approximately 22% and 25% of bile salt levels found in the bile and small intestine of Abcb11.sup.+/+ mice, respectively. In addition, bile salt levels found in treated Abcb11.sup.-/- mice were approximately 4 and 5.4 fold higher than those found in bile and intestine of non-treated Abcb11.sup.-/- mice, respectively.

(124) AAV8-Co-hBSEP can Also Induce Therapeutic Effects in Abcb11.sup.-/- Female Mice

(125) Once the inventors had shown that AAVAnc80-co-hBSEP could induce therapeutic effects in Abcb11.sup.-/- female mice, they evaluated whether these effects could also be achieved by using an AAV vector with serotype 8 expressing the same transgene (AAV8-co-hBSEP). Four-week old Abcb11.sup.-/- female mice were injected intravenously with 6×10^{13} vg/kg of AAV8-co-hBSEP and bled periodically as described in the previous part. Mice were sacrificed at one (n=4) and five (n=6) months after treatment. Non-treated Abcb11.sup.-/- and Abcb11.sup.+/+ mice were used as negative and positive controls, respectively. As in the case of AAVAnc80-co-hBSEP-treated mice, those that received AAV8-co-hBSEP showed a reduction of serum biomarkers, like AST and bilirubin, up to five months post-treatment compared with non-treated Abcb11.sup.-/- mice (FIG. 8A-B). In addition, a significant reduction in hepatomegaly was observed in AAV8-co-hBSEP-treated mice when compared with non-treated Abcb11.sup.-/- mice (FIG. 9A-B). Finally, treatment with AAV8-co-hBSEP was also able to partially restore bile salt secretion in Abcb11.sup.-/- female mice, reaching levels that represented approximately 25% and 98% of bile salt levels found in the bile and small intestine of Abcb11.sup.+/+ mice, respectively (FIG. 10). In addition, bile salt levels found in treated Abcb11.sup.-/- mice were approximately 4.4 and 21 fold higher than those found in bile and intestine of non-treated Abcb11.sup.-/- mice, respectively.

CONCLUSIONS

(126) From these results the inventors can conclude that liver delivery of a codon-optimized version of human BSEP gene from AAV vectors with either Anc80 or 8 serotypes results in a long-lasting therapeutic effect in a clinically relevant animal model of PFIC2 disease. Specifically, both AAVAnc80-co-hBSEP and AAV8-co-hBSEP vectors were able to partially restore bile salt secretion from the liver, resulting in control of transaminase and bilirubin levels, as well as of liver growth in treated mice.

(127) Sequences for Use in Practicing the Invention

(128) Sequences for use in practicing the invention are described below:

(129) TABLE-US-00002 Codon-optimized sequence encoding BSEP (co-BSEP): (SEQ

ID NO: 1) ATGAGCGACTCCGTGATTCTGAGATCAATCAAAAAA

ATTCGGCGAAGAAAATGACGGGTTCGAGAGCGATA

AATCCTATAATAATGACAAGAAGTCTAGGCTGCAG

GACGAGAAGAAGGGCGATGGCGTGCGGGTGGGCTT

CTTTCAGCTGTTCCGGTTCAGCAGCAGCACCGACA

TCTGGCTGATGTTTGTGGGCAGCCTGTGCGCCTTC

CTGCACGGCATCGCACAGCCAGGCGTGCTGCTGAT

CTTTGGCACCATGACAGACGTGTTTCATCGACTACG

ATGTGGAGCTGCAGGAGCTGCAGATCCCTGGCAAA

GCCTGCGTGAACAATACCATCGTGTGGACAAACAG

CTCCCTGAACCAGAATATGACCAACGGCACACGCT

GTGGCCTGCTGAATATCGAGTCTGAGATGATCAAG

TTTGCCAGCTACTATGCAGGAATCGCAGTGGCCGT

GCTGATCACCGGCTACATCCAGATTTGCTTCTGGG

TCATCGCAGCAGCAAGGCAGATCCAGAAGATGAGA

AAGTTCTATTTTCGGAGAATCATGCGGATGGAGAT

CGGCTGGTTTGAAGTCTGTGGGCGAGCTGA

ATACAAGATTCAGCGACGACATCAACAAGATCAAT

GACGCCATCGCCGATCAGATGGCCCTGTTTATCCA

GCGGATGACCAGCACAAATCTGTGGCTTCCTGCTGG

GCTTCTTTAGAGGCTGGAAGCTGACCCTGGTCATC

ATCAGCGTGTCCCCACTGATCGGAATCGGAGCAGC

AACAATCGGCCTGTCTGTGAGCAAGTTCACCGACT

ACGAGTACGCTGAGCTCCCAAGGCAGGAGTGGTG
GCAGATGAAGTGATCAGCAGCATGAGGACCGTGGC
AGCCTTTGGCGGAGAGAAGAGGGAGGTGGAGCGGT
ACGAGAAGAACCTGGTGTTCGCCAGCGGTGGGGC
ATCAGAAAGGGCATCGTGATGGGCTTCTTTACAGG
CTTCGTGTGGTGCCTGATCTTCCTGTGCTACGCCC
TGGCCTTTTGGTATGGCTCCACCCTGGTGCTGGAC
GAGGGAGAGTATACCCCTGGCACACTGGTGCAGAT
TTTCCTGAGCGTGATCGTGGGCGCCCTGAACCTGG
GAAATGCATCCCCATGCCTGGAAGCCTTCGCCACA
GGAAGGGCAGCAGCCACCTCCATCTTCGAGACAAT
CGACCGCAAGCCTATCATCGACTGTATGTCTGAGG
ATGGCTACAAGCTGGACAGGATCAAGGGCGAGATC
GAGTTTCACAATGTGACCTTCCACTATCCCAGCCG
CCCTGAGGTGAAGATCCTGAACGATCTGAATATGG
TCATCAAGCCAGGAGAGATGACCGCCCTGGTGGA
CCCTCTGGAGCAGGCAAGAGCACCGCCCTGCAGCT
GATCCAGCGGTTTTACGACCCTTGCGAGGGAATGG
TGACCGTGGACGGACACGACATCAGGTCCCTGAAC
ATCCAGTGGCTGCGCGATCAGATCGGCATCGTGGA
GCAGGAGCCAGTGCTGTTCTCTACCACAATCGCCG
AGAATATCAGATACGGCCGCGAGGATGCCACAATG
GAGGACATCGTGACGGCCGCCAAGGAGGCCAACGC
CTATAACTTCATCATGGATCTGCCCCAGCAGTTCG
ACACCCTGGTGGGAGAGGGAGGAGGACAGATGTCC
GGAGGCCAGAAGCAGAGAGTGGCCATCGCCAGAGC
CCTGATCCGCAACCCTAAGATCCTGCTGCTGGATA
TGGCCACAAGCGCCCTGGACAATGAGTCCGAGGCT
ATGGTGCAGGAGGTGCTGAGCAAGATCCAGCACGG
CCACACCATCATCTCTGTGGCACACAGGCTGAGCA
CAGTGAGAGCAGCCGACACCATCATCGGCTTTGAG
CACGGCACAGCAGTGGAGAGGGGCACCCACGAGGA
GCTGCTGGAGAGGAAGGGCGTGTACTTCACCCTGG
TGACACTGCAGTCCCAGGGCAACCAGGCCCTGAAT
GAGGAGGACATCAAGGATGCCACAGAGGACGATAT
GCTGGCCCGGACCTTCAGCAGAGGCTCCTATCAGG
ATTCTCTGAGGGCCAGCATCAGGCAGCGGAGCAAG
TCTCAGCTGAGCTACCTGGTGCACGAGCCACCTCT
GGCAGTGGTGGACCACAAGTCCACCTATGAGGAGG
ATCGCAAGGACAAGGACATCCCAGTGCAGGAGGAG
GTGGAGCCTGCACCAAGTGAGGCGCATCCTGAAGTT
TTCCGCCCCAGAGTGGCCCTACATGCTGGTGGGAT
CTGTGGGAGCAGCAGTGAACGGCACCGTGACACCA
CTGTATGCCTTCCTGTTTTCCCAGATCCTGGGCAC
CTTCTCTATCCCCGACAAGGAGGAGCAGCGGTCCC
AGATCAATGGCGTGTGCCTGCTGTTTGTGGCTATG
GGCTGCGTGAGCCTGTTTACACAGTTCCTGCAGGG
CTACGCCTTCGCCAAGAGCGGCGAGCTGCTGACCA
AGCGGCTGAGAAAGTTCGGCTTTAGAGCCATGCTG
GGCCAGGACATCGCCTGGTTTGACGATCTGCGGAA

CAGCCCGCTTGACCAAGACTGGCCACAG
ATGCATCTCAGGTGCAGGGAGCAGCAGGCAGCCAG
ATCGGCATGATCGTGAACCTTCACCAATGTGAC
AGTGGCCATGATCATCGCCTTCAGCTTTTCCTGGA
AGCTGAGCCTGGTCATCCTGTGCTTCTTCCCCTTT
CTGGCCCTGAGCGGAGCAACCCAGACAAGGATGCT
GACCGGCTTTCGCCTCCAGAGACAAGCAGGCCCTGG
AGATGGTGGGCCAGATCACAAACGAGGCCCTGAGC
AATATCAGGACCGTGGCAGGAATCGGCAAGGAGCG
GCGGTTCATCGAGGCCCTGGAGACAGAGCTGGAGA
AGCCTTTCAAGACCGCCATCCAGAAGGCCAACATC
TACGGCTTCTGCTTTGCCTTCGCCCAGTGTATCAT
GTTTCATCGCCAACTCTGCCAGCTACCGCTATGGCG
GCTACCTGATCAGCAATGAGGGCCTGCACTTCAGC
TACGTGTTCAGAGTGATCAGCGCCGTGGTGCTGTC
TGCCACAGCCCTGGGAAGGGCCTTCTCCTACACCC
CATCTTATGCCAAGGCCAAGATCAGCGCCGCCAGG
TTCTTTCAGCTGCTGGACCGCCAGCCACCCATCAG
CGTGTAACAACAGCCGGCGAGAAGTGGGATAATT
TCCAGGGCAAGATCGACTTTGTGGATTGCAAGTTC
ACCTATCCTAGCAGACCAGACTCCCAGGTGCTGAA
TGGCCTGTCCGTGTCTATCAGCCCAGGCCAGACAC
TGGCCTTTGTGGGCTCCTCTGGCTGTGGCAAGTCC
ACCTCTATCCAGCTGCTGGAGCGGTTCTATGACCC
CGATCAGGGCAAAGTGATGATCGACGGCCACGATA
GCAAGAAGGTGAACGTGCAGTTTCTGAGATCCAAT
ATCGGCATCGTGTCTCAGGAGCCTGTGCTGTTTCGC
CTGCTCCATCATGGATAACATCAAGTACGGCGACA
ATACAAAGGAGATCCCAATGGAGAGAGTGATCGCA
GCAGCAAAGCAGGCACAGCTGCACGATTTTCGTGAT
GTCCCTGCCCCGAGAAGTATGAGACAAACGTGGGCT
CTCAGGGCAGCCAGCTGTCCAGGGGGCGAGAAGCAG
AGGATCGCAATCGCCAGGGCCATCGTGCGCGATCC
CAAGATCCTGCTGCTGGACGAGGCCACCAGCGCCC
TGGATACAGAGTCCGAGAAGACCGTGCAGGTGGCC
CTGGACAAGGCCCCGGGAGGGAAGAACATGTATCGT
GATCGCCCACAGACTGAGCACCATCCAGAATGCCG
ACATCATCGCCGTGATGGCCCAGGGCGTGGTCATC
GAGAAGGGCACCCACGAGGAAGTATGGCACAGAA
AGGGGCTTACTACAAACTGGTCACAACAGGCTCAC CTATCTCATAG Codon-optimized
sequence encoding BSEP #2 (co-BSEP-2) (SEQ ID NO: 2)
ATGTCTGATTCTGTGATCCTGAGATCCATCAAGAA
ATTTGGGGAAGAGAATGATGGCTTTGAGTCTGACA
AGAGCTACAACAATGACAAGAAAAGCAGGCTGCAG
GATGAGAAAAAGGGTGATGGTGTGAGAGTGGGCTT
CTTCCAGCTGTTTCAGATTCAGCAGCAGCACAGACA
TCTGGCTGATGTTTGTGGGCAGCCTGTGTGCCTTC
CTGCATGGAATTGCTCAGCCTGGGGTGCTGCTGAT
CTTTGGCACCATGACAGATGTGTTTCATTGACTATG
ATGTGGAAGTCAAGAGCTGCAGATCCCTGGCAAG

GCTTGTGTAACCAACCATGCTGTGGACCAACAG
CAGCCTGAACCAGAACATGACCAATGGCACCAGAT
GTGGCCTGCTGAACATAGAGTCTGAGATGATCAAG
TTTGCCAGCTACTATGCTGGCATTGCTGTGGCAGT
GCTGATCACAGGCTACATCCAGATCTGCTTTTGGG
TCATAGCTGCTGCCAGACAGATCCAGAAGATGAGG
AAGTTCTACTTTAGAAAGGATCATGAGGATGGAAAT
TGGATGGTTTGACTGCAACTCTGTGGGAGAGCTGA
ACACCAGATTCTCTGATGACATCAACAAGATCAAT
GATGCCATTGCTGACCAGATGGCCCTGTTTCATCCA
GAGGATGACCAGCACCATCTGTGGCTTTCTGCTGG
GCTTTTTTCAGAGGCTGGAAGCTGACCCTGGTTATC
ATCTCTGTGTCCCCACTGATTGGCATTGGAGCTGC
CACCATTGGCCTGTCTGTGTCCAAGTTCACAGACT
ATGAGCTGAAAGCCTATGCCAAGGCTGGTGTGTG
GCTGATGAAGTGATCAGCTCCATGAGAACAGTGGC
TGCCTTTGGTGGTGAAAAGAGGGAAGTTGAGAGAT
ATGAGAAGAACCTGGTGTTTGCCCAGAGATGGGGC
ATCAGAAAGGGCATTGTGATGGGATTCTTCACAGG
CTTTGTGTGGTGCCTGATCTTCCTGTGCTATGCCC
TGGCCTTTTGGTATGGCAGCACCCCTGGTTCTTGAT
GAAGGGGAGTACACCCCTGGAACCTCTGGTGCAGAT
CTTTCTGTCTGTGATTGTGGGAGCCCTGAACCTGG
GCAATGCCTCTCCATGTCTGGAAGCCTTTGCCACA
GGCAGAGCTGCTGCTACCAGCATCTTTGAGACAAT
TGACAGAAAGCCCATCATTGACTGCATGTCTGAGG
ATGGCTACAAGCTGGACAGGATCAAAGGGGAGATT
GAGTTCCACAACGTGACCTTTCACTACCCCAGCAG
ACCTGAAGTGAAGATCCTGAATGACCTGAACATGG
TCATCAAGCCTGGGGAGATGACAGCCCTTGTGGGA
CCTAGTGGTGCTGGCAAATCTACAGCCCTGCAGCT
GATCCAGAGATTCTATGACCCCTGTGAAGGCATGG
TCACAGTGGATGGCCATGACATCAGATCTCTGAAC
ATCCAGTGGCTGAGGGACCAGATTGGAATTGTGGA
ACAAGAGCCTGTGCTGTTTCAGCACCAACATTGCAG
AGAACATCAGATATGGCAGGGAAGATGCCACAATG
GAAGATATTGTGCAGGCTGCCAAAGAGGCCAACGC
CTACAACCTTCATCATGGACCTGCCTCAGCAGTTTG
ACACCCTTGTTGGAGAGGGTGGTGGCCAAATGAGT
GGTGGACAGAAACAGAGAGTGGCCATTGCTAGAGC
CCTGATCAGAAACCCCAAGATCCTGCTGCTGGACA
TGGCTACATCTGCCCTGGACAATGAGTCTGAGGCT
ATGGTGCAAGAGGTGCTGAGCAAGATCCAGCATGG
CCACACCATCATTAGTGTGGCCCACAGACTGAGCA
CAGTCAGGGCTGCTGACACAATCATTGGATTTGAG
CATGGCACAGCAGTGGAAAGGGGCACCCATGAGGA
ACTGCTGGAAAGAAAAGGGGTCTACTTCACCCTGG
TCACCCTGCAGTCTCAGGGCAATCAGGCCCTGAAT
GAAGAGGACATCAAGGATGCCACTGAGGATGACAT
GCTGGCCAGAACCTTCAGCAGAGGCAGCTACCAGG

ATAGCCTGACGATCAGACAGAGAAGCAAG
AGCCAGCTGAGCTACCTGGTGCATGAACCTCCACT
GGCTGTGGTGGACCACAAGTCCACCTATGAGGAAG
ATAGGAAGGACAAGGACATCCCTGTGCAAGAAGAG
GTGGAACCTGCTCCTGTCAGAAGAATCCTGAAGTT
TTCTGCCCCTGAGTGGCCCTACATGCTTGTGGGTT
CTGTTGGGGCTGCTGTGAATGGCACAGTGACCCCT
CTGTATGCCTTTCTGTTCTCCCAGATCCTGGGCAC
CTTTAGCATCCCTGACAAAGAGGAACAGAGGTCCC
AGATCAATGGTGTCTGCCTGCTCTTTGTGGCTATG
GGCTGTGTGTCCCTGTTTACCCAGTTCCTGCAGGG
ATATGCCTTTGCTAAGAGTGGGGAGCTGCTCACAA
AGAGGCTGAGAAAGTTTGGCTTCAGAGCCATGCTT
GGCCAGGACATTGCTTGGTTTGATGACCTGAGAAA
CAGCCCTGGGGCTCTGACCACAAGACTGGCTACAG
ATGCTAGCCAGGTGCAGGGTGCAGCAGGCAGCCAA
ATTGGCATGATTGTGAACAGCTTCACCAATGTGAC
AGTGGCCATGATCATTGCCTTCAGCTTCAGCTGGA
AACTGAGCCTTGTGATCCTCTGCTTCTTCCCCTTT
CTGGCCCTGTCTGGGGCTACCCAGACAAGAATGCT
GACTGGCTTTGCCTCCAGAGACAAGCAGGCCCTGG
AAATGGTTGGACAGATCACCAATGAGGCCCTGTCC
AACATCAGGACAGTGGCAGGCATTGGCAAAGAGAG
AAGATTCATTGAGGCCCTTGAGACAGAGCTTGAGA
AGCCCTTCAAGACAGCCATCCAGAAAGCTAACATC
TATGGGTTCTGCTTTGCTTTTGCCCAGTGCATCAT
GTTTCATTGCCAACTCAGCCAGCTACAGATATGGTG
GCTACCTGATCTCTAATGAGGGCCTGCACTTCAGC
TATGTGTTCAGAGTGATCTCTGCTGTGGTGCTGTC
TGCCACTGCTCTGGGCAGAGCCTTTAGCTACACCC
CTAGCTATGCCAAAGCCAAGATCTCTGCAGCCAGA
TTCTTTCAGCTGCTGGATAGACAGCCTCCTATCAG
TGTGTACAACACAGCTGGGGAGAAGTGGGACAAC
TCCAGGGCAAGATTGACTTTGTGGATTGCAAGTTC
ACCTATCCTAGCAGACCAGACTCTCAGGTGCTGAA
TGGACTGAGTGTGTCTATCAGCCCTGGCCAGACAC
TGGCCTTTGTGGGAAGCTCTGGATGTGGCAAGAGC
ACCAGCATCCAGCTGCTTGAGAGGTTCTATGATCC
AGACCAGGGCAAAGTGATGATTGATGGGCATGACA
GCAAGAAAGTGAATGTGCAGTTCCTGAGGTCCAAC
ATTGGGATTGTGTCCCAAGAACCTGTTCTGTTTGC
CTGCAGCATCATGGATAACATTAAGTATGGGGACA
ACACCAAAGAAATCCCTATGGAAAGAGTGATTGCT
GCAGCCAAGCAGGCACAGCTGCATGATTTTGTGAT
GAGCCTGCCTGAGAAGTATGAGACAAATGTGGGCT
CCCAGGGCAGCCAGCTGTCTAGAGGGGAAAAACAG
AGAATTGCCATAGCCAGGGCCATAGTCAGAGATCC
TAAGATTCTGCTCCTGGATGAGGCCACCTCTGCTC
TGGATACAGAGTCTGAAAAGACAGTCCAGGTGGCA
CTGGACAAGGCCAGAGAGGGCAGAACCTGTATTGT

GATTGCCCTGTGCCACAATCCAAAATGCTG
ACATCATTGCAGTGATGGCCCAAGGGGTTGTGATT
GAGAAGGGAACACATGAAGAACTCATGGCCCAAAA
AGGGGCCTATTATAAGCTGGTCACCACTGGCAGCC CCATCAGCTAG Recombinant
AAV vector comprising codon-optimized sequence encoding BSEP (rAAV-co-hBSEP)
(SEQ ID NO: 3) CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAG
GCCGCCCGGGCAAAGCCCCGGGCGTCGGGGCGACCTT
TGGTCGCCCCGGCCTCAGTGAGCGAGCGAGCGCGCA
GAGAGGGAGTGGCCAACCTCCATCACTAGGGGTTCC
TGCGGCCGCGAATTCCATGGTACCAGGCATCAAGA
CACGTGCGCCACCCCCCTCCACCTTGGACACAGGAC
GCTGTGGTTTTCTGAGCCAGGTACAATGACTCCTTT
CGGTAAGTGCAGTGGAAGCTGTACACTGCCCAGGC
AAAGCGTCCGGGCAGCGTAGGCGGGCGACTCAGAT
CCCAGCCAGTGGACTTAGCCCCCTGTTTGCTCCTCC
GATAACTGGGGTGACCTTGGTTAATATTCACCAGC
AGCCTCCCCCGTTGCCCTCTGGATCCACTGCTTA
AATACGGACGAGGACAGGGCCCTGTCTCCTCAGCT
TCAGGCACCACCACTGACCTGGGACAGTGAAGGCC
TGTCGACGGATCCGAGCTCGCCGCCACCATGAGCG
ACTCCGTGATTCTGAGATCAATCAAAAAATTTCGGC
GAAGAAAATGACGGGTTCGAGAGCGATAAATCCTA
TAATAATGACAAGAAGTCTAGGCTGCAGGACGAGA
AGAAGGGCGATGGCGTGCGGGTGGGCTTCTTTCAG
CTGTTCCGGTTCAGCAGCAGCACCGACATCTGGCT
GATGTTTGTGGGCAGCCTGTGCGCCTTCCTGCACG
GCATCGCACAGCCAGGCGTGCTGCTGATCTTTGGC
ACCATGACAGACGTGTTTCATCGACTACGATGTGGA
GCTGCAGGAGCTGCAGATCCCTGGCAAAGCCTGCG
TGAACAATAACCATCGTGTGGACAAACAGCTCCCTG
AACCAGAATATGACCAACGGCACACGCTGTGGCCT
GCTGAATATCGAGTCTGAGATGATCAAGTTTGCCA
GCTACTATGCAGGAATCGCAGTGGCCGTGCTGATC
ACCGGCTACATCCAGATTTGCTTCTGGGTCATCGC
AGCAGCAAGGCAGATCCAGAAGATGAGAAAGTTCT
ATTTTCGGAGAATCATGCGGATGGAGATCGGCTGG
TTTGA CTGTAACTCTGTGGGCGAGCTGAATACAAG
ATTCAGCGACGACATCAACAAGATCAATGACGCCA
TCGCCGATCAGATGGCCCTGTTTATCCAGCGGATG
ACCAGCACAACTCTGTGGCTTCCTGCTGGGCTTCTT
TAGAGGCTGGAAGCTGACCCTGGTCATCATCAGCG
TGTCCTCCACTGATCGGAATCGGAGCAGCAACAATC
GGCCTGTCTGTGAGCAAGTTCACCGACTACGAGCT
GAAAGCCTACGCCAAGGCAGGAGTGGTGGCAGATG
AAGTGATCAGCAGCATGAGGACCGTGGCAGCCTTT
GGCGGAGAGAAGAGGGAGGTGGAGCGGTACGAGAA
GAACCTGGTGTTTCGCCAGCGGTGGGGCATCAGAA
AGGGCATCGTGATGGGCTTCTTTACAGGCTTCGTG
TGGTGCTGATCTTCCTGTGCTACGCCCTGGCCTT
TTGGTATGGCTCCACCCTGGTGCTGGACGAGGGAG

AGTATACCTACACTGGTGCAGATTTTCCTG
AGCGTGATCGTGGGCGCCCTGAACCTGGGAAATGC
ATCCCCATGCCTGGAAGCCTTCGCCACAGGAAGGG
CAGCAGCCACCTCCATCTTCGAGACAATCGACCGC
AAGCCTATCATCGACTGTATGTCTGAGGATGGCTA
CAAGCTGGACAGGATCAAGGGCGAGATCGAGTTTC
ACAATGTGACCTTCCACTATCCCAGCCGCCCTGAG
GTGAAGATCCTGAACGATCTGAATATGGTCATCAA
GCCAGGAGAGATGACCGCCCTGGTGGGACCCTCTG
GAGCAGGCAAGAGCACCGCCCTGCAGCTGATCCAG
CGGTTTTACGACCCTTGCGAGGGAATGGTGACCGT
GGACGGACACGACATCAGGTCCCTGAACATCCAGT
GGCTGCGCGATCAGATCGGCATCGTGGAGCAGGAG
CCAGTGCTGTTCTCTACCACAATCGCCGAGAATAT
CAGATACGGCCGCGAGGATGCCACAATGGAGGACA
TCGTGCAGGCCGCCAAGGAGGCCAACGCCTATAAC
TTCATCATGGATCTGCCCCAGCAGTTCGACACCCT
GGTGGGAGAGGGAGGAGGACAGATGTCCGGAGGCC
AGAAGCAGAGAGTGGCCATCGCCAGAGCCCTGATC
CGCAACCCTAAGATCCTGCTGCTGGATATGGCCAC
AAGCGCCCTGGACAATGAGTCCGAGGCTATGGTGC
AGGAGGTGCTGAGCAAGATCCAGCACGGCCACACC
ATCATCTCTGTGGCACACAGGCTGAGCACAGTGAG
AGCAGCCGACACCATCATCGGCTTTGAGCACGGCA
CAGCAGTGGAGAGGGGCACCCACGAGGAGCTGCTG
GAGAGGAAGGGCGTGTACTTACCCCTGGTGACACT
GCAGTCCCAGGGCAACCAGGCCCTGAATGAGGAGG
ACATCAAGGATGCCACAGAGGACGATATGCTGGCC
CGGACCTTCAGCAGAGGCTCCTATCAGGATTCTCT
GAGGGCCAGCATCAGGCAGCGGAGCAAGTCTCAGC
TGAGCTACCTGGTGCACGAGCCACCTCTGGCAGTG
GTGGACCACAAGTCCACCTATGAGGAGGATCGCAA
GGACAAGGACATCCCAGTGCAGGAGGAGGTGGAGC
CTGCACCAGTGAGGCGCATCCTGAAGTTTTCCGCC
CCAGAGTGGCCCTACATGCTGGTGGGATCTGTGGG
AGCAGCAGTGAACGGCACCGTGACACCACTGTATG
CCTTCCTGTTTTCCAGATCCTGGGCACCTTCTCT
ATCCCCGACAAGGAGGAGCAGCGGTCCCAGATCAA
TGGCGTGTGCCTGCTGTTTGTGGCTATGGGCTGCG
TGAGCCTGTTTACACAGTTCCTGCAGGGCTACGCC
TTCGCCAAGAGCGGCGAGCTGCTGACCAAGCGGCT
GAGAAAGTTCGGCTTTAGAGCCATGCTGGGCCAGG
ACATCGCCTGGTTTGACGATCTGCGGAACAGCCCA
GGCGCCCTGACCACAAGACTGGCCACAGATGCATC
TCAGGTGCAGGGAGCAGCAGGCAGCCAGATCGGCA
TGATCGTGAACCTCCTTACCAATGTGACAGTGGCC
ATGATCATCGCCTTCAGCTTTTCCTGGAAGCTGAG
CCTGGTCATCCTGTGCTTCTTCCCCTTTCTGGCCC
TGAGCGGAGCAACCCAGACAAGGATGCTGACCGGC
TTCGCCTCCAGAGACAAGCAGGCCCTGGAGATGGT

GGGCCAGCAAAACGAGGCCCTGAGCAATATCA
GGACCGTGGCAGGAATCGGCAAGGAGCGGCGGTTC
ATCGAGGCCCTGGAGACAGAGCTGGAGAAGCCTTT
CAAGACCGCCATCCAGAAGGCCAACATCTACGGCT
TCTGCTTTGCCTTCGCCCAGTGTATCATGTTTCATC
GCCAACTCTGCCAGCTACCGCTATGGCGGCTACCT
GATCAGCAATGAGGGCCTGCACTTCAGCTACGTGT
TCAGAGTGATCAGCGCCGTGGTGCTGTCTGCCACA
GCCCTGGGAAGGGCCTTCTCCTACACCCCATCTTA
TGCCAAGGCCAAGATCAGCGCCGCCAGGTTCTTTC
AGCTGCTGGACCGCCAGCCACCCATCAGCGTGTAC
AACACAGCCGGCGAGAAGTGGGATAATTTCCAGGG
CAAGATCGACTTTGTGGATTGCAAGTTCACCTATC
CTAGCAGACCAGACTCCCAGGTGCTGAATGGCCTG
TCCGTGTCTATCAGCCCAGGCCAGACACTGGCCTT
TGTGGGCTCCTCTGGCTGTGGCAAGTCCACCTCTA
TCCAGCTGCTGGAGCGGTTCTATGACCCCGATCAG
GGCAAAGTGATGATCGACGGCCACGATAGCAAGAA
GGTGAACGTGCAGTTTCTGAGATCCAATATCGGCA
TCGTGTCTCAGGAGCCTGTGCTGTTTCGCCTGCTCC
ATCATGGATAACATCAAGTACGGCGACAATAACAAA
GGAGATCCCAATGGAGAGAGTGATCGCAGCAGCAA
AGCAGGCACAGCTGCACGATTTTCGTGATGTCCCTG
CCCGAGAAGTATGAGACAAACGTGGGCTCTCAGGG
CAGCCAGCTGTCCAGGGGGCGAGAAGCAGAGGATCG
CAATCGCCAGGGCCATCGTGCGCGATCCCAAGATC
CTGCTGCTGGACGAGGCCACCAGCGCCCTGGATAC
AGAGTCCGAGAAGACCGTGCAGGTGGCCCTGGACA
AGGCCCGGGAGGGAAGAACATGTATCGTGATCGCC
CACAGACTGAGCACCATCCAGAATGCCGACATCAT
CGCCGTGATGGCCCAGGGCGTGGTCATCGAGAAGG
GCACCCACGAGGAACCTGATGGCACAGAAAGGGGCT
TACTACAAACTGGTCACAACAGGCTCACCTATCTC
ATAGGGATCCATATGATATCAATAAAGACCTCTTA
TTTTTCATTCATCAGGTGTGGTTGGTTTTTTTGTGT
GGGGGCTCGAGATCTGAGGAACCCCTAGTGATGGA
GGCGGCCGCAGGAACCCCTAGTGATGGAGTTGGCC
ACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGC
CGGGCGACCAAAGGTGCGCCGACGCCCGGGCTTTG
CCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGC TGCCTGCAG Recombinant
AAV vector comprising codon-optimized sequence encoding BSEP #2 (rAAV-co-
hBSEP-2) (SEQ ID NO: 4) CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAG
GCCGCCCCGGGCAAAGCCCCGGGCGTCGGGCGACCTT
TGGTCGCCCCGGCCTCAGTGAGCGAGCGAGCGCGCA
GAGAGGGAGTGGCCAACCTCCATCACTAGGGGTTCC
TGCGGCCGCGAATTCCATGGTACCAGGCATCAAGA
CACGTGCGCCACCCCCTCCACCTTGGACACAGGAC
GCTGTGGTTTCTGAGCCAGGTACAATGACTCCTTT
CGGTAAGTGCAGTGGAAGCTGTACACTGCCCAGGC
AAAGCGTCCGGGCAGCGTAGGCGGGCGACTCAGAT

CCCAGCTTGTAGCCCCCTGTTTGCTCCTCC
GATAACTGGGGTGACCTTGGTTAATATTCACCAGC
AGCCTCCCCCGTTGCCCCCTCTGGATCCACTGCTTA
AATACGGACGAGGACAGGGCCCTGTCTCCTCAGCT
TCAGGCACCACCACTGACCTGGGACAGTGAAGGCC
TGTCGACGGATCCGAGCTCGCCGCCACCATGTCTG
ATTCTGTGATCCTGAGATCCATCAAGAAATTTGGG
GAAGAGAATGATGGCTTTGAGTCTGACAAGAGCTA
CAACAATGACAAGAAAAGCAGGCTGCAGGATGAGA
AAAAGGGTGATGGTGTGTCAGAGTGGGCTTCTTCCAG
CTGTTTCAGATTCAGCAGCAGCACAGACATCTGGCT
GATGTTTGTGGGCAGCCTGTGTGCCTTCCTGCATG
GAATTGCTCAGCCTGGGGTGCTGCTGATCTTTGGC
ACCATGACAGATGTGTTCAATTGACTATGATGTGGA
ACTGCAAGAGCTGCAGATCCCTGGCAAGGCTTGTG
TGAACAACACCATTGTGTGGACCAACAGCAGCCTG
AACCAGAACATGACCAATGGCACCAGATGTGGCCT
GCTGAACATAGAGTCTGAGATGATCAAGTTTGCCA
GCTACTATGCTGGCATTGCTGTGGCAGTGCTGATC
ACAGGCTACATCCAGATCTGCTTTTGGGTCATAGC
TGCTGCCAGACAGATCCAGAAGATGAGGAAGTTCT
ACTTTAGAAGGATCATGAGGATGGAAATTGGATGG
TTTGA CTGCAACTCTGTGGGAGAGCTGAACACCAG
ATTCTCTGATGACATCAACAAGATCAATGATGCCA
TTGCTGACCAGATGGCCCTGTTTCATCCAGAGGATG
ACCAGCACCATCTGTGGCTTTCTGCTGGGCTTTTT
CAGAGGCTGGAAGCTGACCCTGGTTATCATCTCTG
TGTCCTCCACTGATTGGCATTGGAGCTGCCACCATT
GGCCTGTCTGTGTCCAAGTTCACAGACTATGAGCT
GAAAGCCTATGCCAAGGCTGGTGTGTTGTGGCTGATG
AAGTGATCAGCTCCATGAGAACAGTGGCTGCCTTT
GGTGGTGAAAAGAGGGGAAGTTGAGAGATATGAGAA
GAACCTGGTGTTTGCCCAGAGATGGGGCATCAGAA
AGGGCATTGTGATGGGATTCTTCACAGGCTTTGTG
TGGTGCCTGATCTTCCTGTGCTATGCCCTGGCCTT
TTGGTATGGCAGCACCCTGGTTCTTGATGAAGGGG
AGTACACCCCTGGA ACTCTGGTGCAGATCTTTCTG
TCTGTGATTGTGGGAGCCCTGAACCTGGGCAATGC
CTCTCCATGTCTGGAAGCCTTTGCCACAGGCAGAG
CTGCTGCTACCAGCATCTTTGAGACAATTGACAGA
AAGCCCATCATTGACTGCATGTCTGAGGATGGCTA
CAAGCTGGACAGGATCAAAGGGGAGATTGAGTTCC
ACAACGTGACCTTTCACTACCCCAGCAGACCTGAA
GTGAAGATCCTGAATGACCTGAACATGGTCATCAA
GCCTGGGGAGATGACAGCCCTTGTGGGACCTAGTG
GTGCTGGCAAATCTACAGCCCTGCAGCTGATCCAG
AGATTCTATGACCCCTGTGAAGGCATGGTCACAGT
GGATGGCCATGACATCAGATCTCTGAACATCCAGT
GGCTGAGGGACCAGATTGGAATTGTGGAACAAGAG
CCTGTGCTGTTTCAGCACCACCATTGCAGAGAACAT

CAGATGATGAGAGATGCCACAATGGAAGATA
TTGTGCAGGCTGCCAAAGAGGCCAACGCCTACAAC
TTCATCATGGACCTGCCTCAGCAGTTTGACACCCT
TGTTGGAGAGGGTGGTGGCCAAATGAGTGGTGGAC
AGAAACAGAGAGTGGCCATTGCTAGAGCCCTGATC
AGAAACCCCAAGATCCTGCTGCTGGACATGGCTAC
ATCTGCCCTGGACAATGAGTCTGAGGCTATGGTGC
AAGAGGTGCTGAGCAAGATCCAGCATGGCCACACC
ATCATTAGTGTGGCCACAGACTGAGCACAGTCAG
GGCTGCTGACACAATCATTGGATTTGAGCATGGCA
CAGCAGTGGAAAGGGGGCACCCATGAGGAACTGCTG
GAAAGAAAAGGGGTCTACTTCACCCTGGTCACCCT
GCAGTCTCAGGGCAATCAGGCCCTGAATGAAGAGG
ACATCAAGGATGCCACTGAGGATGACATGCTGGCC
AGAACCTTCAGCAGAGGCAGCTACCAGGATAGCCT
GAGAGCCAGCATCAGACAGAGAAGCAAGAGCCAGC
TGAGCTACCTGGTGCATGAACCTCCACTGGCTGTG
GTGGACCACAAGTCCACCTATGAGGAAGATAGGAA
GGACAAGGACATCCCTGTGCAAGAAGAGGTGGAAC
CTGCTCCTGTCAGAAGAATCCTGAAGTTTTCTGCC
CCTGAGTGGCCCTACATGCTTGTGGGTTCTGTTGG
GGCTGCTGTGAATGGCACAGTGACCCCTCTGTATG
CCTTTCTGTTCTCCCAGATCCTGGGCACCTTTAGC
ATCCCTGACAAAGAGGAACAGAGGTCCCAGATCAA
TGGTGTCTGCCTGCTCTTTGTGGCTATGGGCTGTG
TGTCCCTGTTTACCCAGTTCCTGCAGGGATATGCC
TTTGCTAAGAGTGGGGAGCTGCTCACAAAGAGGCT
GAGAAAGTTTGGCTTCAGAGCCATGCTTGGCCAGG
ACATTGCTTGGTTTGATGACCTGAGAAACAGCCCT
GGGGCTCTGACCACAAGACTGGCTACAGATGCTAG
CCAGGTGCAGGGTGCAGCAGGCAGCCAAATTGGCA
TGATTGTGAACAGCTTCACCAATGTGACAGTGGCC
ATGATCATTGCCTTCAGCTTCAGCTGGAAACTGAG
CCTTGTGATCCTCTGCTTCTTCCCCTTTCTGGCCC
TGTCTGGGGCTACCCAGACAAGAATGCTGACTGGC
TTTGCCTCCAGAGACAAGCAGGCCCTGGAAATGGT
TGGACAGATCACCAATGAGGCCCTGTCCAACATCA
GGACAGTGGCAGGCATTGGCAAAGAGAGAAGATTC
ATTGAGGCCCTTGAGACAGAGCTTGAGAAGCCCTT
CAAGACAGCCATCCAGAAAGCTAACATCTATGGGT
TCTGCTTTGCTTTTGCCAGTGCATCATGTTCAAT
GCCAACTCAGCCAGCTACAGATATGGTGGCTACCT
GATCTCTAATGAGGGCCTGCACTTCAGCTATGTGT
TCAGAGTGATCTCTGCTGTGGTGCTGTCTGCCACT
GCTCTGGGCAGAGCCTTTAGCTACACCCCTAGCTA
TGCCAAAGCCAAGATCTCTGCAGCCAGATTCTTTC
AGCTGCTGGATAGACAGCCTCCTATCAGTGTGTAC
AACACAGCTGGGGAGAAGTGGGACAACCTCCAGGG
CAAGATTGACTTTGTGGATTGCAAGTTCACCTATC
CTAGCAGACCAGACTCTCAGGTGCTGAATGGACTG

AGTGTGTCATCAGCCCTGGCCAGACACTGGCCCTT
TGTGGGAAGCTCTGGATGTGGCAAGAGCACCAAGCA
TCCAGCTGCTTGAGAGGTTCTATGATCCAGACCAG
GGCAAAGTGATGATTGATGGGCATGACAGCAAGAA
AGTGAATGTGCAGTTCCTGAGGTCCAACATTGGGA
TTGTGTCCCAAGAACCTGTTCTGTTTGCCTGCAGC
ATCATGGATAACATTAAGTATGGGGACAACACCAA
AGAAATCCCTATGGAAAGAGTGATTGCTGCAGCCA
AGCAGGCACAGCTGCATGATTTTGTGATGAGCCTG
CCTGAGAAGTATGAGACAAATGTGGGCTCCCAGGG
CAGCCAGCTGTCTAGAGGGGAAAAACAGAGAATTG
CCATAGCCAGGGCCATAGTCAGAGATCCTAAGATT
CTGCTCCTGGATGAGGCCACCTCTGCTCTGGATAC
AGAGTCTGAAAAGACAGTCCAGGTGGCACTGGACA
AGGCCAGAGAGGGCAGAACCTGTATTGTGATTGCC
CATAGGCTGTCCACAATCCAAAATGCTGACATCAT
TGCAGTGATGGCCCAAGGGGTTGTGATTGAGAAGG
GAACACATGAAGAACTCATGGCCCAAAAAGGGGCC
TATTATAAGCTGGTCACCACTGGCAGCCCCATCAG
CTAGGGATCCATATGATATCAATAAAGACCTCTTA
TTTTCATTCATCAGGTGTGGTTGGTTTTTTTGTGT
GGGGGCTCGAGATCTGAGGAACCCCTAGTGATGGA
GGCGGCCGCAGGAACCCCTAGTGATGGAGTTGGCC
ACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGC
CGGGCGACCAAAGGTCGCCCCGACGCCCGGGCTTTG
CCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGC TGCCTGCAG Alpha 1
antitrypsin promoter (SEQ ID NO: 5)
CGCCACCCCCTCCACCTTGGACACAGGACGCTGTG
GTTTCTGAGCCAGGTACAATGACTCCTTTCGGTAA
GTGCAGTGGAAGCTGTACACTGCCAGGCAAAGCG
TCCGGGCAGCGTAGGCGGGCGACTCAGATCCCAGC
CAGTGGACTTAGCCCCTGTTTGCTCCTCCGATAAC
TGGGGTGACCTTGTTAATATTCACCAGCAGCCTC
CCCCGTTGCCCCTCTGGATCCACTGCTTAAATACG GACGAGGACA Human minimal
bile salt export pump (ABCB11) gene promoter (SEQ ID NO: 6)
TTCCCAAGCACACTCTGTGTTTGGGGTTATTGCTC
TGAGTATGTTTCTCGTATGTCACCTGAACTGTGCTT
GGGCTGCCCTTAGGGACATTGATCCTTAGGCAAAT
AGATAATGTTCTTGAAAAAGTTTGAATTCTGTTCA GTGCT Mouse minimal Bile
Salt export pump (ABCB11) gene promoter (SEQ ID NO: 7)
GGTTCCTGCTTTGAGTATGTTTCGACCTTTCCTCTC
ATGTCACTGAACTGTGCTAGATCTGGACTTTAGGC
CATTGACCTATAAGCAAATAGATAGTGTTCTTAAA
AAAGCCTGATTTCTGTTCAATGCTTTATTACCATG AAAAC Synthetic poly A sequence
(SEQ ID NO: 8) AATAAAGACCTCTTATTTTCATTCATCAGGTGTGG
TTGGTTTTTTTGTGTGGGGGC

Claims

1. A nucleic acid construct comprising a nucleic acid sequence encoding BSEP having SEQ ID NO: 1 or SEQ ID NO: 2.
 2. The nucleic acid construct of claim 1 further comprising a liver-specific promoter.
 3. The nucleic acid construct of claim 1 further comprising a polyadenylation signal sequence.
 4. The nucleic acid construct of claim 1 further comprising 5'ITR and 3'ITR sequences of AAV.
 5. The nucleic acid construct of claim 1 comprising a nucleic acid sequence of SEQ ID NO: 3 or SEQ ID NO: 4.
 6. An expression vector comprising the nucleic acid construct of claim 1.
 7. The expression vector of claim 6 wherein said vector is a viral vector.
 8. A viral particle comprising the nucleic acid construct of claim 1.
 9. An AAV particle comprising the nucleic acid construct of claim 1.
 10. A host cell comprising the nucleic acid construct of claim 1.
 11. A pharmaceutical composition comprising the nucleic acid construct of claim 1, and a pharmaceutically acceptable excipient.
 12. A method of treating Progressive Familial Intrahepatic Cholestasis Type 2 (PFIC2) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the nucleic acid construct of claim 1.
 13. The method of claim 12 wherein said subject is a neonate, an infant, a child or an adult.
 14. A method of producing the viral particle of claim 8, comprising: a) culturing a packaging cell comprising the nucleic acid construct in a culture medium, and b) harvesting the viral particle from cell culture supernatant and/or inside the packaging cell.
 15. A kit comprising the nucleic acid construct of claim 1, in one or more containers.
 16. The nucleic acid construct of claim 1 comprising SEQ ID NO: 1.
 17. The nucleic acid construct of claim 1 comprising SEQ ID NO: 2.
 18. The nucleic acid construct of claim 2 wherein the liver-specific promoter is an alpha-1-antitrypsin promoter or a bile salt-inducible promoter.
 19. The nucleic acid construct of claim 3 wherein the polyadenylation signal sequence comprises SEQ ID NO: 8.
-